

# Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force

Kathleen M. McTigue, MD; Russell Harris, MD, MPH; Brian Hemphill, MD, MPH; Linda Lux, MPA; Sonya Sutton, BSPH; Audrina J. Bunton, BA; Kathleen N. Lohr, PhD

Obesity is an increasingly significant U.S. health problem. Over 4 decades, the prevalence of obesity (body mass index [BMI], kilograms of weight divided by height in meters squared [ $\text{kg}/\text{m}^2$ ],  $\geq 30$ ) has increased from 13% to 31% in adults and the prevalence of overweight (BMI 25–29.9  $\text{kg}/\text{m}^2$ ) has increased from 31% to 34%.<sup>1</sup> Concurrent increases occurred in adolescents and children.<sup>2–4</sup> Obesity is especially common in African Americans, some Hispanic populations, and Native Americans and some health sequelae reflect similar ethnic differences.<sup>5,6</sup> Obesity is more common in women, and overweight is more common in men.<sup>5</sup> Obesity is a risk factor for major causes of death, including cardiovascular disease, numerous cancers, and diabetes,<sup>7</sup> and is linked with markedly diminished life expectancy.<sup>8,9</sup> Osteoarthritis, gall bladder disease, sleep apnea, respiratory impairment, diminished mobility, and social stigmatization are associated with obesity.<sup>10</sup>

Health risk is better established for obese persons than for overweight persons. However, overweight status also carries risk<sup>11</sup>; even mild-to-moderate overweight in young adults predicts subsequent obesity,<sup>12</sup> and weight gain is associated with adverse

outcomes.<sup>13</sup> Visceral fat versus subcutaneous fat is particularly linked with adverse cardiovascular profiles in diverse ethnic and racial groups.<sup>14–20</sup> Body composition varies with race and ethnicity (eg, Asians may be more likely<sup>21</sup> and African Americans less likely to accumulate visceral fat than whites<sup>15,22,23</sup>); health implications may also vary.<sup>14–20</sup>

Estimated direct obesity costs are 5.7% of total U.S. health expenditures.<sup>24</sup> Expected lifetime costs for cardiovascular disease and its risk factors increase by 20% with mild obesity, by 50% with moderate obesity, and by nearly 200% with severe obesity.<sup>25</sup>

We reviewed the medical literature for effectiveness of adult obesity screening—the conscious measurement of weight status to clinically address body weight—and treatment. Although obesity may seem obvious, only 42% of obese U.S. adults report receiving health care advice to lose weight.<sup>26</sup>

In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended periodic height and weight measurement.<sup>7</sup> Increased obesity prevalence, therapeutic changes, and accumulating evidence of associated health risk necessitate an update. The

From the Departments of Medicine and Epidemiology, University of Pittsburgh (McTigue), Pittsburgh, Pennsylvania; Department of Medicine and Cecil G. Sheps Center for Health Services Research, University of North Carolina School of Medicine (Harris), Chapel Hill, North Carolina; Department of Internal Medicine, University of New Mexico (Hemphill), Albuquerque, New Mexico; RTI International (Lux, Sutton, Lohr), Research Triangle Park, North Carolina; Cecil G. Sheps Center for Health Services Research, University of North Carolina School of Medicine (Bunton), Chapel Hill, North Carolina.

The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the U.S. Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Address correspondence to Russell Harris, MD, MPH, Cecil G. Sheps Center for Health Services Research, CB # 7590, 725 Airport Road, Chapel Hill, NC 27516. Phone: 919-966-2949. Fax: 919-966-3811. E-mail: rharris@med.unc.edu.

Reprints are available from the AHRQ Web site ([www.preventiveservices.ahrq.gov](http://www.preventiveservices.ahrq.gov)) or through the National Guideline Clearinghouse™ ([www.guideline.gov](http://www.guideline.gov)). Print copies of this article, along with other USPSTF evidence summaries and Recommendations and Rationale statements, are available by subscription to the *Guide to Clinical Preventive Services, Third Edition, Periodic Updates*. The cost of this subscription is \$60 and is available through the AHRQ Publications Clearinghouse (call 1-800-358-9295 or e-mail [ahrqpubs@ahrq.gov](mailto:ahrqpubs@ahrq.gov)).

This first appeared in *Ann Intern Med*. 2003;139(11):933–949.

Research Triangle Institute (RTI)–University of North Carolina Evidence-based Practice Center developed a systematic review of evidence to assist the USPSTF in this process.

## Methods

We developed an analytic framework of obesity screening components, with key questions, and eligibility criteria (Appendix Table 1). Randomized controlled trials (RCTs) or systematic reviews of RCTs were preferred evidence: when lacking, we evaluated cohort and nonrandomized controlled studies. Because of limited long-term data, we accepted pharmacotherapy efficacy trials with 6 months minimum follow-up; otherwise, we required at least 12 months. Study quality was rated using USPSTF criteria (Appendix Table 2).<sup>27</sup>

We examined the USPSTF's 1996 review,<sup>7</sup> then searched MEDLINE® and the Cochrane Library for articles published in English between January 1994 and February 2003.<sup>27</sup> We evaluated well-done systematic reviews from the National Institutes of Health (NIH),<sup>11</sup> the Canadian Task Force on Preventive Health Care (CTFPHC),<sup>28</sup> the University of York for the U.K. National Health Service (NHS),<sup>29</sup> the National Task Force on the Prevention and Treatment of Obesity,<sup>30</sup> and the *British Medical Journal's Clinical Evidence*.<sup>31</sup> We used the last as the sole systematic review source for drug efficacy, as the comprehensive reviews were outdated.

To compare treatment efficacy across reviews, we extracted data from each review's evidence tables on studies with current interventions and at least 1-year follow-up. We also drew from their general conclusions. We then reviewed primary literature not covered by prior reviews. At least 2 authors independently reviewed abstracts and articles, excluding those not meeting eligibility criteria, then abstracting eligible articles. We abstracted or calculated 95% confidence intervals (CIs) for treatment efficacy from available data whenever possible. When sample size was not reported with variance,<sup>32,33</sup> baseline sample was used.

## Role of the Funding Sources

The U.S. Agency for Healthcare Research and Quality (AHRQ) funded this research. Agency staff and USPSTF members participated in the initial study design and reviewed interim analyses and the final manuscript.

## Results

Although no RCTs evaluated obesity screening efficacy, we found studies that address obesity's health risks, treatment efficacy, and weight loss' health implications.

## Weight and Health Risk

Longitudinal data showed J-shaped or U-shaped relationships between absolute mortality and BMI<sup>34–45</sup>; elevated risk at low BMI may partly reflect smoking,<sup>35,37,42</sup> or BMI's limitations in approximating fat mass.<sup>46</sup> BMI of lowest mortality risk varied, but was generally within the normal range for men and the normal-to-overweight range for women.<sup>34–45</sup> Morbidity risk increased fairly linearly with BMI. Risk was strongest for cardiovascular disorders.<sup>37,43,47</sup> Breast, colon, uterine, and ovarian cancer incidence increased with BMI.<sup>44,48</sup>

In the United States, the association between excess body weight and mortality may be weaker for African Americans than for whites.<sup>41,42,49</sup> However, race-specific data are rare, and sample size concerns limit conclusions. Mortality risk from excess weight may lessen with age; health risks from obesity are unclear beyond age 74.<sup>50</sup>

## Approaches to Screening

BMI, the most common screening test for obesity, is easy to measure, highly reliable, and closely correlated (0.7–0.8) with adult body fat.<sup>7,51,52</sup> Validity may vary by population characteristics, including ethnicity<sup>53–55</sup> and possibly age.<sup>51,56</sup> Clinical relevance is established by prospective links with diverse health outcomes.<sup>37,40–43,47,57</sup>

Waist circumference and the waist-to-hip ratio may capture the increased cardiovascular risk for

central adiposity—even among non-obese persons.<sup>44,58–61</sup> Of these, waist circumference more closely approximates visceral adiposity, particularly in African Americans.<sup>15,20</sup> Skinfold thickness measurement requires training for accuracy, so was judged undesirable.<sup>7</sup> We focused on BMI because BMI is linked with the broadest range of health outcomes, entry criteria for most treatment studies are BMI-based, and such trials typically report weight or BMI change.

## Effect of Counseling and Behavioral Interventions on Body Weight

Counseling aims to promote change in diet and/or exercise; behavioral interventions are strategies to help patients acquire the skills, motivations, and support to change diet and exercise patterns. For comparison with other treatments, we consider counseling for diet, exercise, or some combination, potentially with behavioral theory, in aggregate. Importantly, each counseling component includes diverse options, possibly in combination. Also, while primary-care-based physical activity counseling has uncertain efficacy,<sup>62</sup> physical activity has diverse health benefits<sup>63</sup> and obesity's cardiovascular risk may be reduced by fitness.<sup>64</sup> Prior systematic reviews found modest counseling and behavioral intervention effects, while more recent RCTs showed consistent findings (Table 1).

In 29 trials with at least 1-year follow-up, the NIH review found average weight change in diet and/or physical activity groups (some including behavioral therapy) of 1.9 kg to –8.8 kg (mean, –3.3 kg), corrected for change in controls (Table 1).<sup>11</sup> Counseling for low-calorie diets (1,000–1,200 kilocalories [kcal] per day) reduced body weight by an average 8% over 3 to 12 months and decreased abdominal fat. Although very-low-calorie diets produced greater initial weight loss than low-calorie diets, results were similar beyond 1 year. Counseling for physical activity (24 RCTs) led to 2% to 3% loss of weight and reduced abdominal fat. Combined diet and physical activity counseling produced greater reduction of weight and abdominal fat than either approach alone. Behavior therapy was a useful adjunct to diet and/or physical

activity counseling. Longer-term efficacy depended on continued intervention.

The U.K. NHS review found that behavioral interventions, combined with diet or exercise, appeared effective and long-term maintenance strategies useful.<sup>29</sup> In 24 studies, mean net weight change (intervention arms corrected for controls) was –3 kg over 12 to 60 months (Table 1). The CTFPHC review found weight reduction was most effective during supervised dietary treatment, with subsequent gradual weight regain.<sup>28</sup> In 6 trials, net weight change was –0.2 kg to –4.5 kg after 24 to 84 months.

We identified 17 additional counseling RCTs.<sup>65–82</sup> We examined weight loss and loss maintenance trials separately.<sup>67,73</sup> Limitations included loss to follow-up (5%–38%) and differential attrition between treatments. External validity concerns included volunteer enrollment versus random community sampling and poor gender and ethnic diversity.

To compare diverse programs (Appendix Table 3), we assessed intervention mode (group or individual), components (diet, exercise, behavioral), and intensity (low, moderate, high). Intensity was rated by frequency of person-to-person contact in the first 3 months. Moderate intensity was defined as monthly contact, high intensity was defined as more frequent contact, and low intensity was defined as less frequent contact.

As shown in Figure 1 (a summary of trials for which the difference in mean weight change between intervention and control groups could be calculated, as close as possible to 1-year follow-up), high-intensity trials were most likely to be successful, generally achieving 3 kg to 5 kg of weight loss. Two intensive trials reported success frequency. In 1 trial,<sup>67</sup> mean weight loss due to intervention was 3.4 kg (CI, 2.6–4.2); 30% more persons in the treatment group than in the control group lost at least 5% of their body weight, in the other, a net 5.5 kg loss ( $P < 0.001$ ) corresponded with 38% in the intervention group losing 7% total body weight.<sup>81</sup>

**Table 1. Summary of Findings from Prior Systematic Reviews and Our Updated Searches of Obesity Treatment Efficacy<sup>11\*</sup>**

Intervention Type	Evidence Source	Months of Follow-up		RCTs
		Range	Median	Number
Counseling and behavioral therapy	U.S. NIH <sup>11</sup>	12 to 60	12	29
	U.K. NHS <sup>29</sup>	12 to 60	12	24
	CTFPHC <sup>28</sup>	24 to 60	24	6
	Updated searches (1)	12 to 54	12	12
	Updated searches (2)	12 to 54	12	13
Pharmacotherapy (orlistat or sibutramine)	<i>BMJ Clin Evid</i> <sup>81</sup>	0.5 to 24	NA	17†
	Updated searches	6 to 12	6	10
Surgery	U.S. NIH <sup>11</sup>	12 to 48	24	5
	U.K. NHS <sup>29</sup>	12 to 48	30	6
	CTFPHC <sup>28</sup>	24 to 60	36	4
	Updated searches	18 to 18	18	2

\* Data reflect weight loss RCTs that have at least 1 year of follow-up; the longest follow-up reported is shown. Only counseling and pharmacotherapy trials that provided data on treatment effect with and without adjustment for control are included. Weight maintenance studies are not shown. Surgery data reflect only current procedures (gastric bypass, adjustable gastric banding, vertical banded gastroplasty); because trials compare 2 techniques (ie, no comparison to non-surgical control), results are unadjusted for control. Results of updated searches for counseling results are shown with (1) and without (2) inclusion of a trial combining alternative counseling strategies with pharmacotherapy.<sup>65</sup>

† Data presented are for 7 studies of sibutramine and 10 studies of orlistat only.

*BMJ Clin Evid*, *British Medical Journal's Clinical Evidence*; CTFPHC, Canadian Task Force on Preventive Health Care; NA, data not available to do appropriate calculation; NHS, U.K. National Health Service; NIH, National Institutes of Health; NR, not reported; RCT, randomized controlled trial.

Because not all trials used a null control (many compared one counseling intervention with another), our treatment efficacy estimates (intervention effect minus control) may be conservative. Of 11 high-intensity interventions to promote weight loss, 6 used a true control; 4 were successful (2.5–5.5 kg loss beyond controls in 12–54 mos),<sup>66,67,70,81</sup> and 2 showed borderline<sup>76</sup> or transient<sup>69</sup> weight reduction (Table 2). In 5 trials, 1 high-intensity intervention led to more weight loss than another.<sup>65,72,74,78,82</sup> Moderate-intensity interventions showed mixed results.<sup>71,79</sup> Two of the 3 low-intensity weight loss interventions were ineffective.<sup>77,83</sup>

Successful interventions typically included 2 to 3 components (diet, exercise, and behavioral therapy).

Only 1 trial<sup>65</sup> examined a combination of counseling and pharmacotherapy. In this trial, adding lifestyle counseling to sibutramine therapy led to a mean weight reduction of 7.3 kg (CI, 1.6–13.0), and adding a low-calorie diet to counseling and sibutramine therapy led to a mean weight reduction of 12.8 kg (CI, 8.2–17.4).<sup>65</sup>

Twelve- to 18-month prolonged follow-up was reported in 3 high-intensity weight loss studies,<sup>67,70,76</sup> 2 of which included long-term maintenance strategies.<sup>66,76</sup> Although participants regained weight, modest net loss ( $\geq 2$  kg) was maintained for 24 to 36 months in 3 of 4 interventions.<sup>67,70,76</sup>

Trials designed to maintain weight loss showed some success.<sup>68,73</sup> One promoted an additional 5 kg

**Table 1. Summary of Findings from Prior Systematic Reviews and Our Updated Searches of Obesity Treatment Efficacy<sup>11\*</sup> (cont)**

Treatments Compared with Control	Weight Change: Intervention Group (kg)		Weight Change: Control Group (kg)		
	Number	Range	Mean	Range	Mean
	54	8 to -21.6	-5.7	1.9 to -8.8	-3.3
	51	5.4 to -12.9	-4.5	1.4 to -10.6	-3.0
	12	2.7 to -9.2	-3.3	-0.2 to -4.5	-2.1
	22	9.2 to -17	-3.7	0.88 to -5.8	-2.0
	24	9.2 to -17.9	-4.6	0.88 to -12.3	-2.6
	NR	NR	NR	-2.5 to -4.4	NR
	11	-3.3 to -13.1	-6.5	-2.8 to -5.8	-4.0
	7	-9.7 to -159	-76.0	NA	NA
	8	-9.7 to -57.9	-45.1	NA	NA
	9	-17 to -45.5	-29.9	NA	NA
	4	-34 to < -46	NA	NA	NA

(1-yr) loss.<sup>68</sup> In another, weight-focused counseling promoted weight maintenance in 36% more participants than exercise-focused counseling.<sup>73</sup>

Overall, counseling promoted modest average weight loss (3–5 kg). Multi-component, intensive interventions including behavioral therapy most often led to weight loss. Maintenance strategies helped sustain loss.

## Effect of Pharmacotherapy Interventions on Body Weight


Pharmacological obesity treatment has changed substantially in the past decade. Safety concerns have eliminated several options. Evidence of the efficacy of sibutramine (a dopamine, norepinephrine, and serotonin re-uptake inhibitor) and orlistat (a gastrointestinal lipase inhibitor) evidence has increased. Both are approved for people with BMIs of 30 kg/m<sup>2</sup> or more, or people who have BMIs greater than 27 kg/m<sup>2</sup> with other risk factors (eg, hypertension, diabetes, or dyslipidemia) in combination with lifestyle change. Efficacy trials have also examined several drugs developed for non-weight-related purposes.

A recent obesity pharmacotherapy systematic review found that sibutramine promoted 2.8 to 4.2 kg of weight loss (7 RCTs) over 8 to 52 weeks in healthy adults and those with controlled hypertension, but weight regain followed treatment discontinuation.<sup>31</sup> Orlistat's efficacy was similar (mean 3.5 kg loss in 10 RCTs of 1–2 yrs duration). Phentermine (7.4 kg average loss in 1 RCT) and mazindol (3.8 kg average loss in 1 RCT, but no longer manufactured in the U.S.) caused modest weight loss in adults more than 15% overweight; other small RCTs showed limited and inconsistent efficacy of diethylpropion (2 RCTs) or fluoxetine (2 RCTs).

We identified 18 additional RCTs meeting eligibility criteria: 7 evaluated sibutramine<sup>32,33,84–88</sup>; 8 evaluated orlistat<sup>89–96</sup>; 2 evaluated metformin<sup>81,97</sup>; and 1 evaluated multiple drugs.<sup>98</sup> Three trials examined maintenance strategies.<sup>84,92,93</sup> Attrition (3%–50%) and poor adherence data were primary quality limitations. Generalizability issues were similar to the counseling trials.

In 6 weight loss trials (Figure 2),<sup>32,33,85–88</sup> sibutramine-treated participants lost 2.8 kg

**Figure 1. Differences in Mean Weight Loss Between Intervention and Control Groups for Counseling and Behavioral Interventions**




Note: Only studies for which this difference can be calculated are included. Error bars represent 95% confidence intervals and are presented for studies in which those data are available. Data presented are as close as possible to 1-year follow-up.

\* Statistically significant ( $P < 0.05$ ) but with insufficient data to calculate 95% confidence intervals.

B, behavioral therapy; D, diet; E, exercise; EP, exercise program; EQ, exercise equipment; L, lottery entry; MR, meal replacement; SES, socioeconomic status; +++, high intensity; ++, moderate intensity; +, low intensity.

**Figure 2. Differences in Mean Weight Loss Between Intervention and Control Groups for Pharmacotherapy Interventions**



Note: Data points (diamonds, circles, and squares) represent mean weight change in intervention group (kg) – mean weight change in placebo group (kg). Only studies for which the difference in mean weight loss could be calculated are included; each arm is represented by a data point. Error bars represent 95% confidence intervals and are presented for studies in which those data are available. Intensity of co-interventions is not assessed as most trials provided insufficient information for evaluation.

\* Statistically significant ( $P < 0.05$ ) but with insufficient data to calculate 95% confidence intervals.

B, behavioral therapy; BID, twice daily; D, diet; E, exercise; QD, daily; TID, 3 times daily.

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions**

Study, Year	Goal and Components	Sample Size (N), Race, Sex, and Age†	Body Mass Index (kg/m <sup>2</sup> )‡	Study Duration	Groups§
Stevens et al, 2001 <sup>70</sup>	L + M D, E, B G + I	N: 1191 White: 79% Black: 18% F: 34% Age: 43 yrs	31	18 mos	Weight loss Control
				36 mos	Weight loss Control
Kuller et al, 2001 <sup>66</sup>	L + M D, E, B G + I	N: 535 White: 92% F: 100% Age: 47 yrs	25	54 mos	Lifestyle change Assessment only
Tuomilehto et al, 2001 <sup>67</sup>	L D, E, B G	N: 522 Race: NR F: 67% Age: 55 yrs	31	1 yr	Intervention Control
				2 yrs	Intervention Control
				1 yr	Intervention Control
Fogelholm et al, 2000 <sup>76</sup>	L + M D, E, B G	N: 82 Race: NR F: 100% Age: 30–45 yrs	34	1 yr	1st PA program 2nd PA program Control
				2 yrs	1st PA program 2nd PA program Control
Knowler et al, 2002 <sup>81</sup>	L + M D, E, B G + I	N: 3234 White: 55% Black: 20% Hispanic: 16% American Indian: 5% Asian: 4% F: 68% Age: 51 yrs	34	2.8 yrs	Metformin Lifestyle Placebo  Metformin Lifestyle Placebo
Jakicic et al, 1999 <sup>72</sup>	L D, E, B G	N: 148 Race: NR F: 100% Age: 25–45 yrs	Weight 20%–75% higher than ideal body wt	18 mos	Long-bout PA Short-bout PA + EQ Short-bout PA
Jones et al, 1999 <sup>69</sup>	L D, B G + I	N: 102 White: 60% Black: 40%	34	6 mos	Weight loss Control

B, behavioral therapy; D, diet; E, exercise; EQ, exercise equipment; G, group-based; I, individual-based; L, weight loss; M, maintenance of weight loss; NR, not reported; NS, not significant; OXCHECK, Oxford and Collaborators Check; PA, physical activity; SES, socioeconomic status.

† Mean values unless otherwise noted.

‡ Baseline mean or range unless otherwise noted.

§ See Appendix Table 3 for details.

|| Compared with control unless otherwise noted.



**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Weight Change	Between-Group Differences <sup>II</sup>	P Value	Patients Lost to Follow-up	Study Quality
-2.0 kg 0.7 kg	-2.7 kg	≤ 0.001	8% at 36 mos	Good
-0.2 kg 1.8 kg	-2.0 kg	≤ 0.001		
-0.09 kg 2.4 kg	-2.5 kg	≤ 0.001	5%	Good
-4.2 kg -0.8 kg	-3.4 kg	≤ 0.001	8%	Good
-3.5 kg -0.8 kg	-2.7 kg	≤ 0.001		
<u>Freq 5% loss</u> NR NR	30%	0.001		
-0.7 kg -0.6 kg 2.0 kg	-2.7 kg -2.6 kg	0.06	10%	Fair
5.9 kg 9.2 kg 9.7 kg	-3.8 kg -0.5 kg	0.07		
-2.1 kg -5.6 kg -0.1 kg	-2.0 kg -5.5 kg	≤ 0.001	7.5%	Good
<u>Freq &gt; 7% loss</u> NR 38% NR				
-5.8 kg -7.4 kg -3.7 kg	-2.1 kg -3.7 kg (referent)	≤ 0.05 NS all other pairs	22% (13%–29% per group)	Fair
-3.2 kg -1.8 kg	-1.4 kg	0.05	9%	Fair

*continue*

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Study, Year	Goal and Components	Sample Size (N), Race, Sex, and Age†	Body Mass Index (kg/m <sup>2</sup> )‡	Study Duration	Groups§
					<b>High Intensity</b>
		F: 52% Intervention: 57 yrs Control: 59 yrs		12, 18 24, 30 mos	
Sbrocco et al, 1999 <sup>74</sup>	L D, E, B G	N: 24 Race: NR F: 100% Age: 40–43 yrs (varied by group)	33	12 mos	Behavioral choice Traditional behavioral treatment
Wadden et al, 2001 <sup>65</sup>	L D, E, B G	N: 53 Race: NR F: 100%  Age Drug: 46 Drug, L: 41 Drug, D, L: 40	36–39	1 yr	Sibutramine + diet + lifestyle Sibutramine + lifestyle Sibutramine
Ashley et al, 2001 <sup>82</sup>	L D, E, B G + I	N: 113 Race: NR F: 100% Age: 41–42 yrs (varied by group)	25–35	1 yr	Primary care visit, meal replacement Nutritionist, meal replacement Nutritionist alone
Wing and Anglin, 1996 <sup>78</sup>	L D, E, B G	N: 93 Black: 17% White: 80% Other: 2% Female Black: 75% White: 66% Age Black: 49 yrs White: 52 yrs	Black: 37 White: 38	1 yr	Behavioral therapy, with very-low-calorie diet  Behavioral therapy with low-calorie diet
Leermakers et al, 1999 <sup>73</sup>	M D, E, B G	N: 67 White: 94% F: 80% Age: 50.8 yrs	31	18 mos	Weight-focused maintenance program  PA-focused maintenance program  Weight-focused program  PA-focused program

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Weight Change		Between-Group Differences <sup>II</sup>	P Value	Patients Lost to Follow-up	Study Quality
NR	NR	NS			
-10.1 kg -4.3 kg	-5.76 kg		0.01	17%	Fair
-16.6 kg -11.1 kg -3.8 kg 59% of drug + diet + lifestyle participants had lost ≥ 15% of weight at 1 yr	-12.8 kg -7.3 kg (referent)		≤ 0.05 ≤ 0.05	32%	Fair
-3.5 kg -7.7 kg -3.4 kg	-0.1 kg -3.7 kg (referent)		NS ≤ 0.05	32%–38%	Fair
Black: -13 kg White: -17 kg  Black: -11 kg White: -13 kg  Weight loss is approximate, from graphic data	Black: -2 kg White: -4 kg  (referent)  Weight loss is approximate, from graphic data		NR	19%	Fair
3.1 kg  5.2 kg	-2.1 kg		≤ 0.05 ≤ 0.01	15% at 6 mos; 28% at 18 mos	Fair
90% original weight loss maintained  54% original weight loss maintained	-36%				

*continue*

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Study, Year	Goal and Components	Sample Size (N), Race, Sex, and Age†	Body Mass Index (kg/m <sup>2</sup> )‡	Study Duration	Groups§
					<b>Moderate Intensity</b>
Lindholm et al, 1995 <sup>79</sup>	L D, E G	N: 681 Race: NR F: 15% Range: 30–59 yrs	<u>Intervention</u> Men: 27 Women: 30  <u>Control</u> Men: 27 Women: 29	18 mos	6 sessions of health care advice  Usual care
Swinburn et al, 1999 <sup>71</sup>	L D, B G	N: 176 <u>Intervention</u> European: 69% Maori: 12% Pacific Islander: 14% Other: 4%  <u>Control</u> European: 75% Maori: 7% Pacific Islander: 4% Other: 3%  F <u>intervention</u> : 21% F <u>Control</u> : 35%  <u>Intervention</u> : 53.2% <u>Control</u> : 52.3%	<u>Intervention</u> 84 kg <u>Control</u> 85 kg	12 mos	Reduced fat diet  Usual diet

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Weight Change	Between-Group Differences <sup>II</sup>	P Value	Patients Lost to Follow-up	Study Quality
NR NR	-0.25 kg	NS	6%	Good
-3.1 kg 0.4 kg	-3.5 kg	≤ 0.001	38%	Fair

*continue*

Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)

Study, Year	Goal and Components	Sample Size (N), Race, Sex, and Age†	Body Mass Index (kg/m <sup>2</sup> )‡	Study Duration	Groups§
					<b>Low Intensity</b>
Jeffery and French, 1997 <sup>77</sup>	L D, E G	N: 822 Each group White: 76%–94% F: 81% Age: 31–37 yrs (varied by group)	Men: 28 Women: 26–28	12 mos	Lifestyle edu Edu + lottery Control  Lifestyle edu Edu + lottery Control  Lifestyle edu Edu + lottery Control
Bemelmans et al, 2000 <sup>83</sup>	L D G	N: 266 Race: NR F Intervention: 51% F Control: 63% Female: 51% Age: 54–55 yrs (differed by group)	30	52 wks	Dietary interventions with group meetings and mailings Leaflet of Dutch nutritional guidelines
Rothacker et al, 2001 <sup>68</sup>	M D I	N: 75 Race: NR F: 100% Range: 18–55 yrs	25	1 yr	Pre-measured low-calorie liquid supplements Low-energy, low-fat foods
OXCHECK Study Group 1995 <sup>80</sup>	L D I	N: 2205 Race: NR F: 47% Range: 35–64 yrs	NR	NR	Health checks Standard care

**Table 2. Randomized Controlled Trials of Counseling and Behavioral Interventions (cont)**

Weight Change	Between-Group Differences <sup>1</sup>	P Value	Patients Lost to Follow-up	Study Quality
Men 0.72 lb 0.21 lb 1.94 lb	-1.22 lb -1.73 lb	NS NS	14%	Good
Women (High SES): 1.03 lb 0.51 lb 1.38 lb	-0.35 lb -0.87 lb	NS NS		
Women (High SES): 2.11 lb 3.23 lb 1.30 lb	+0.81 lb +1.93 lb	NS NS		
Men: 0.5 kg/m <sup>2</sup> Women: 0.3 kg/m <sup>2</sup>	Men: 0.1 kg/m <sup>2</sup> Women: 0.1 kg/m <sup>2</sup>	NS NS	8%	Fair (but non-randomized)
Men: 0.4 kg/m <sup>2</sup> Women: 0.3 kg/m <sup>2</sup>				
-6.3 kg  -1.3 kg	-5 kg	≤ 0.001	17%	Fair
NR	At follow-up, those with health checks were 0.38 kg/m <sup>2</sup> less than controls	≤ 0.05	25%	Fair

(CI, 1.6–4.0) to 7.8 kg (CI, 5.9–9.7) more than patients given a placebo (Table 3). Frequency of response, when recorded, was high; 27% (CI, 18–36) to 65% (CI, 60–70) of sibutramine-treated patients achieved 5% loss and 6% (CI, 1–10) to 34% (CI, 26–40) lost 10%.<sup>33,85–88</sup> A 5% loss occurred in 19% (CI, 9–29) to 53% (CI, 36–70) more of drug-treated participants than control participants, and a 10% loss in 5% (CI, –1 to 10) to 27% (CI, 18–36) more.

In 6 trials,<sup>90, 91–94,96</sup> participants treated with a typical orlistat dose (120 mg 3 times daily) lost significantly more weight (2.8 kg [CI, 1.8– 3.7] to 4.5 kg [CI not calculable]) than did controls. In a sixth, not statistically significant trial, orlistat-treated participants lost 5.8 kg more than controls.<sup>95</sup> In the 3 trials reporting response rates, 10% loss occurred in 14% (CI, 10–19) to 38% (CI, 29–47) of orlistat-treated participants, and such response occurred more often by 9% (CI, –2 to 20) to 19% (CI, 8–30) in orlistat-treated participants than controls.<sup>89,91,96</sup>

In 1 trial comparing drug and lifestyle interventions, those treated with metformin lost 2 kg more than those given a placebo but lost less than participants in the lifestyle arm.<sup>81</sup> Another trial showed no metformin effect.<sup>97</sup> A multidrug trial showed sibutramine-treated people lost significantly more weight (13.4 kg) than those treated with orlistat (8 kg) or metformin (9 kg).<sup>98</sup>

Maintenance studies showed moderate success. In 1,<sup>84</sup> sibutramine, taken 6 months for weight loss and 18 months for weight maintenance, promoted a net 4 kg (CI, 2.4–5.6) loss versus placebo. A corresponding 44% (CI, 37–50) of sibutramine versus 16% (CI, 6–25) of placebo participants maintained 80% of initial weight loss. Likewise, successful dieters treated with orlistat lost more weight and over 1 year were more likely to maintain 75% of their initial loss than those treated with placebo ( $P < 0.05$ ).<sup>92</sup> In a third trial, participants treated with 1 or 2 years of orlistat lost “significantly more” weight over 2 years than placebo participants.<sup>93</sup> However, during the second year, orlistat was no more effective than placebo, and discontinuing therapy with the drug led to excess weight gain

(eg, mean weight gain during the second year among those who discontinued orlistat was 6.3 kg vs 3.1 kg among those who took placebo throughout).<sup>93</sup>

Overall, pharmacotherapy with sibutramine and orlistat promoted modest mean weight loss (3–5 kg) beyond that of controls; prolonged drug courses helped sustain this loss up to 2 years. Phentermine and mazindol had similar short-term efficacy but are not approved for long-term use.<sup>31</sup> Metformin, diethylpropion, and fluoxetine showed mixed efficacy.

## Surgical Approaches

Surgical obesity treatment is limited to patients with BMIs exceeding 40 kg/m<sup>2</sup> or patients with BMIs of 35 kg/m<sup>2</sup> or more who have associated severe health complications and have not responded to other treatment modalities.<sup>99</sup> Bariatric surgery is restrictive or malabsorptive, and current techniques are primarily restrictive. Gastric bypass involves complete gastric partitioning with anastomosis of the proximal gastric segment to a jejunal loop. Adjustable gastric banding involves placing an inflatable band around the stomach that can be adjusted to different diameters.<sup>100</sup> Vertical banded gastroplasty entails partial gastric partitioning at the proximal gastric segment with placement of a gastric outlet stoma of fixed diameter.<sup>28</sup> Practice patterns appear to be shifting away from this technique. These procedures can be performed open or laparoscopically. Although the duodenal switch procedure—a relatively new malabsorptive technique—is fairly common in practice, we found no RCTs evaluating its effectiveness.

Because of practical and ethical constraints to a true randomized, blinded, placebo-controlled trial of surgery for obesity, high-quality evidence is limited. The 3 prior systematic reviews of obesity therapy primarily examined randomized unblinded trials comparing surgical techniques (eg, no non-surgical controls).

The U.S. NIH reviewed 5 randomized trials, finding 10 kg to 159 kg of surgical weight loss over 12 to 48 months in patients receiving surgery (Table 1).<sup>11</sup> Of 7 U.K. NHS-reviewed trials, 6 showed weight loss with both gastric bypass (mean reduction, 45–65 kg) and gastroplasty



(mean reduction, 30–35 kg).<sup>29</sup> The CTFPHC analyzed 4 surgical randomized trials and 1 prospective cohort study<sup>28</sup> and found a mean weight loss of 17 kg to 46 kg after 2 to 5 years.

We identified 3 additional randomized trials, all evaluated gastric banding over 1 to 2 years (Table 4).<sup>100–102</sup> In addition to lack of non-surgical controls, quality concerns included lack of cointerventions and comorbidity information. None showed significantly different weight loss between arms, but all treatments promoted considerable loss (17 to > 40 kg).

In addition, we identified a large, controlled, cohort study evaluating surgery efficacy: the Swedish Obese Subjects (SOS) study,<sup>103,104</sup> a multi-center trial of surgical patients (equally divided among gastric banding, vertical banded gastroplasty, and gastric bypass) and nonrandomized, matched, non-surgical controls.<sup>104</sup> At 2 years, weight loss was 28 kg (CI, 26.9–29.1) among surgical patients versus 0.5 kg (CI, –0.2 to 1.2) among controls. Weight reduction after gastric banding, vertical banded gastroplasty, and gastric bypass was 21% (standard deviation [SD] 12), 23% (SD 10), and 33% (SD 10), respectively. After 8 years, a subset analysis showed an average 20 kg (CI, 18.0–22.0) weight loss for 251 surgical patients and a 0.7 kg (CI, –0.8 to 2.2) loss for 232 controls.<sup>104</sup> Overall, surgery promoted substantial, prolonged weight loss (10–159 kg over 1–5 years) in patients with extreme obesity.

## Intermediate Health Outcomes and Sustained Weight Loss

The U.S. NIH systematic review established that counseling-based weight loss (generally 5–10 kg) can improve intermediate health outcomes such as blood pressure, glycemic control, and serum lipids.<sup>11</sup> We assessed the effect of pharmacotherapy-associated weight loss on serum lipids and glucose. Since the prior drug review did not cover these outcomes, we abstracted these data from the primary literature it covered, in addition to the more recent articles.

We found mixed evidence for improved glucose tolerance with sibutramine-induced weight loss.<sup>32,33,84,86,87,105</sup> Orlistat generally,<sup>90,96,106–109</sup> but not always,<sup>110</sup> improved glucose parameters. This

inconsistency may in part be due to medication alterations accompanying weight loss; in 1 trial, orlistat-treated patients with diabetes were more likely (17% vs 8%,  $P < 0.05$ ) to decrease or discontinue diabetes medications than controls,<sup>90</sup> and glycosylated hemoglobin was reduced only when adjusted for these alterations.

Seven trials and 1 review linked orlistat with total cholesterol reduction.<sup>90,92,106–111</sup> Sibutramine showed less consistent total cholesterol findings: no significant drug versus placebo effect in 6 trials,<sup>33,84,86,87,112,113</sup> improvement in 3 others.<sup>32,114,115</sup> Orlistat was frequently (but not always)<sup>116</sup> associated with reduced low-density lipoprotein (LDL) cholesterol.<sup>90,92–94,96,106–108,110,115</sup> Sibutramine had inconsistent LDL effects.<sup>32,84–86,90,96,113,114</sup> Neither drug consistently affected high-density lipoprotein cholesterol<sup>32,33,90,96,105,113,114,116,117</sup> or triglycerides.<sup>33,84–87,90,94,96,105,107,110,112–114</sup>

Surgical cohort studies suggest that large amounts of weight loss may lead to dramatic improvements in glucose metabolism,<sup>118</sup> lipid profiles,<sup>119,120</sup> and blood pressure. Notably, hypertension tended to recur within 3 to 10 years in the SOS group<sup>121</sup>; although weight regain accompanied this recurrence, all surgical groups had maintained at least a 20 kg average loss.

## Ultimate Health Outcomes and Sustained Weight Loss

We found less evidence for effects of weight loss on ultimate (generally symptomatic) health outcomes. Limited observational data suggest intentional weight loss in obese persons (particularly in those with co-morbidity) can reduce mortality.<sup>122,123</sup> Two large RCTs show that behaviorally mediated weight loss can prevent diabetes (58% reduction,  $P < 0.05$ ) among those with glucose intolerance.<sup>67,81</sup> A smaller (31%; CI, 17–43) reduction in diabetes incidence was seen among similar metformin-treated patients.<sup>81</sup> Patients treated surgically (non-RCT data) may experience diabetes resolution (eg, 90% follow-up of 300 surgical patients, initially 50% glucose intolerant, initially 50% with diabetes, showed 91% to have normal fasting glucose and glycosylated

Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions

Study, Year	Drug Dose (mg)	Sample Size (N), Co-Interventions	Race, Sex, Age,† Baseline BMI‡	Length, Goal	Groups
<b>Sibutramine</b>					
Wirth and Krause, 2001 <sup>88</sup>	15 mg daily either continuous or intermittent	All participants: No formal diet, exercise, or behavioral program  Written dietary information	N: 1102 White: 99.8% Female: 77%  <u>Sibutramine:</u> Cont: 43 yrs Int: 43 yrs Placebo: 44 yrs  <u>Sibutramine:</u> Cont: 34.7 kg/m <sup>2</sup> Int: 34.9 kg/m <sup>2</sup> Placebo: 35.0 kg/m <sup>2</sup>	44 wks, L	Sibutramine cont Sibutramine int Placebo  Sibutramine cont Sibutramine int Placebo  Sibutramine cont Sibutramine int Placebo
Dujovne et al, 2001 <sup>85</sup>	20 mg daily	D All participants: Step I American Heart Association diet (1,500 kcal/day for females, 1,800 kcal/day for males)	N: 322 White: 82% Black: 12% Indian or Pakistani: 1% Mexican American: 2% Other: 3%  Drug: 56% female Placebo: 51% female  Drug: 45 yrs Placebo: 46 yrs  Sibutramine: 35.1 kg/m <sup>2</sup> Placebo: 35.5 kg/m <sup>2</sup>	24 wks, L	Sibutramine Placebo  Sibutramine Placebo  Sibutramine Placebo
Fujioka et al, 2000 <sup>86</sup>	Titrated up to 20 mg daily	D All participants: 250–500 kcal/day caloric deficit diet with individual dietary counseling	N: 175 White: 73% Black: 17% Other: 10% Female: 47%  Sibutramine: 53.5 yrs Placebo: 55.0 yrs  Sibutramine: 34.1 kg/m <sup>2</sup> Placebo: 33.8 kg/m <sup>2</sup>	24 wks, L	Sibutramine Placebo  Sibutramine Placebo  Sibutramine Placebo

B, behavioral therapy; bid, twice daily; BMI, body mass index; cont, continuous; D, diet; E, exercise; GI, gastrointestinal; int, intermittent; L, weight loss; M, maintenance of weight loss; NR, not reported; tid, three times daily.

† Values are means unless otherwise indicated.

‡ Presented as baseline mean or range unless otherwise noted.

§ Compared with control unless otherwise noted.

||  $P = 0.02$  vs placebo.

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Weight Change	Between-Group Differences§	Patients Lost		to Follow-up and Adverse Events	Trial Quality
			P Value		
-3.8 kg -3.3 kg -0.2 kg	-3.6 kg -3.1 kg		< 0.001	<u>Sibutramine (continuous):</u> Dropout: 79/405 Due to adverse event: 25/405 Adverse event rate: 303/405	Good
<u>5% loss:</u> 65% 63% 35%	30% 28%		< 0.001	<u>Sibutramine (intermittent):</u> Dropout: 80/395 Due to adverse event: 13/395 Adverse event rate: 283/395	
<u>10% loss:</u> 32% 33% 13%	19% 20%		< 0.001	<u>Placebo:</u> Dropout: 55/201 Due to adverse event: 9/201 Adverse event rate: 151/201	
-4.9 kg -0.6 kg	-4.3 kg		≤ 0.05	<u>Sibutramine:</u> Dropout: 29.6% Due to adverse event: 9.9% Due to hypertension: 0.6%	Fair
<u>5% loss:</u> 42% 8%	34%		< 0.05	<u>Placebo:</u> Dropout: 33.8% Due to adverse event: 6.9% Due to hypertension: 1.9%	
<u>10% loss:</u> 12% 3%	9%		< 0.05		
-3.7 kg -0.4 kg	-3.3 kg		≤ 0.5	<u>Sibutramine:</u> Dropout: 29/89 Due to adverse event: 9/89	Fair
<u>5% loss:</u> 27% 1%	26%		< 0.001	<u>Placebo:</u> Dropout: 25/86 Due to adverse event: 10/86	
<u>10% loss:</u> 6% 1%	5%		0.12		

continue

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Study, Year	Drug Dose (mg)	Sample Size (N), Co-Interventions	Race, Sex, Age,† Baseline BMI‡	Length, Goal	Groups
<b>Sibutramine, continued</b>					
Gokcel et al, 2001 <sup>32</sup>	10 mg bid	D All participants: 25 kcal/kg ideal body weight diet, with counseling at baseline	N: 60 Race: NR Female: 100%  Sibutramine: 47 yrs Placebo: 49 yrs  Sibutramine: 39.3 kg/m <sup>2</sup> Placebo: 37.4 kg/m <sup>2</sup>	24 wks, L	Sibutramine Placebo
Smith and Goulder, 2001 <sup>87</sup>	10 mg or 15 mg daily	D All participants: dietary advice	N: 485 White: 99% Other: 1% Female: 80%  Sibutramine: 10 mg: 41 yrs 15 mg: 43 yrs Placebo: 42 yrs  Sibutramine: 10 mg group: 32.9 kg/m <sup>2</sup> 15 mg group: 32.7 kg/m <sup>2</sup> Placebo: 32.4 kg/m <sup>2</sup>	52 wks, L	Sibutramine: 10 mg Sibutramine: 15 mg Placebo  Sibutramine: 10 mg Sibutramine: 15 mg Placebo  Sibutramine: 10 mg Sibutramine: 15 mg Placebo
McNulty et al, 2003 <sup>33</sup>	15–20 mg daily	D Standard dietary advice by a dietitian or nurse	N: 195 Race: NR Female: 56% 15 mg group: 49 yrs 20 mg group: 48 yrs Placebo: 51 yrs  Sibutramine: 15 mg group: 36.3 kg/m <sup>2</sup> 20 mg group: 37.5 kg/m <sup>2</sup> Placebo: 36.2 kg/m <sup>2</sup>	12 mos, L	Sibutramine: 15 mg Sibutramine: 20 mg Placebo  Sibutramine: 15 mg Sibutramine: 20 mg Placebo  Sibutramine: 15 mg Sibutramine: 20 mg Placebo
James et al, 2000 <sup>84</sup>	10–20 mg daily	D,E,B All participants: high-intensity individualized 600 kcal deficit diet	N: 467 “Almost all” white Afro-Caribbean: 2% Asian: 1.5% Female: 84%  Sibutramine: 41 yrs Placebo: 40 yrs  Sibutramine: 36.5 kg/m <sup>2</sup> Placebo: 36.6 kg/m <sup>2</sup>	80 wks, M (following 6 mos L phase)	Sibutramine Placebo  Sibutramine Placebo

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Weight Change	Between-Group Differences§	Patients Lost P Value	to Follow-up and Adverse Events	Trial Quality
-3.9 kg 0.36 kg	-4.3 kg	< 0.0001	<u>Sibutramine:</u> Dropout: 1/30 Due to adverse event: 1/30  <u>Placebo:</u> Dropout: 5/30 Due to adverse event: NR	Fair
-4.4 kg -6.4 kg -1.6 kg <u>5% Loss:</u> 39% 57% 20% <u>10% Loss:</u> 19% 34% 7%	-2.8 kg -4.8 kg  19% 37%  12% 27%	< 0.01  < 0.01  < 0.01	<u>Sibutramine 10 mg:</u> Dropout: 67/161 Due to adverse event: 2/161 Adverse event rate: 20/161  <u>Sibutramine 15 mg:</u> Dropout: 79/161 Due to adverse event: 2/161 Adverse event rate: 18/161  <u>Placebo:</u> Dropout: 83/163 Due to adverse event: 4/163 Adverse event rate: 24/163	Fair
-5.5 kg -8.0 kg -0.2 kg <u>5% Loss:</u> 46% 65% 12% <u>10% Loss:</u> 14% 27% 0%	-5.3 kg -7.8 kg  34% 53%  14% 27%	< 0.001 < 0.001  Sibutramine "significantly more"  NR	<u>Sibutramine 15 mg:</u> Dropout: 19/68 Due to adverse event: NR  <u>Sibutramine 20 mg:</u> Dropout: 13/62 Due to adverse event: NR  <u>Placebo:</u> Dropout: 18/64 Due to adverse event: NR	Fair
-8.9 kg -4.9 kg <u>Maintaining</u> <u>&gt; 80% of</u> <u>original loss:</u> 41% 14%	-4 kg   27%	< 0.001  < 0.001	<u>Sibutramine:</u> Dropout: 148/352 Due to adverse event: 48/352  <u>Placebo:</u> Dropout: 58/115 Due to adverse event: 6/115	Fair

continue

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Study, Year	Drug Dose (mg)	Co-Interventions	Sample Size (N), Race, Sex, Age,† Baseline BMI‡	Length, Goal	Groups
<b>Orlistat</b>					
Muls et al, 2001 <sup>91</sup>	120 mg	D All participants: Moderate-intensity dietary advice from a dietitian (-600 kcal/day)	N: 294 Race: NR  Orlistat: 82% female Placebo: 78% female  Orlistat: 50 yrs Placebo: 48 yrs  33 kg/m <sup>2</sup>	24 wks, L	Orlistat Placebo  Orlistat Placebo  Orlistat Placebo
Van Gaal et al, 1998 <sup>89</sup>	30, 60, 120, or 240 mg tid	D All participants: high-intensity dietary advice from a dietitian	N: 613 Race: NR Female: 77% Range: 40–44 yrs (varied by group) 34–35 kg/m <sup>2</sup> (varied by group)	52 wks, L	Orlistat: 30 mg Orlistat: 60 mg Orlistat: 120 mg Orlistat: 240 mg Placebo  Orlistat: 30 mg Orlistat: 60 mg Orlistat: 120 mg Orlistat: 240 mg Placebo
Micic et al, 1999 <sup>94</sup>	120 mg tid	D All participants: mildly hypocaloric diet with dietary advice	N: 119 Race: NR  Orlistat: 70% female Placebo: 78% female  Orlistat: 46 yrs Placebo: 45 yrs (median ages)  Orlistat: 34.8 kg/m <sup>2</sup> Placebo: 35.2 kg/m <sup>2</sup>	24 wks, L	Orlistat Placebo

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Weight Change	Between-Group Differences§	P Value	Patients Lost to Follow-up and Adverse Events	Trial Quality
-4.66 kg -1.88 kg <u>Mean change:</u> -5.3% -2.3% <u>5% loss:</u> 64% 39% <u>10% loss:</u> 23% 13%	-2.78 kg  -3%  25%  10%	< 0.001  ≤ 0.001  NR  NR	<u>Orlistat:</u> Dropout: 19/147 (13%) Adverse event rate: 80%   GI adverse event rate: 64%  <u>Placebo:</u> Dropout: 16/147 (11%) Adverse event rate: 67% GI adverse event rate: 38%	Good
-8.5% -8.8% -9.8% -9.3% -6.5% <u>10% Loss:</u> 28% 28% 37% 38% 19%	-2% -2.3% -3.3% -2.8%  9% 9% 18% 19%	< 0.001     NR	<u>Orlistat 30 mg:</u> Dropout: 29/122 Due to adverse event: 7/122 Adverse event rate: 79%  <u>Orlistat 60 mg:</u> Dropout: 29/124 Due to adverse event: 6/124 Adverse event rate: 83%  <u>Orlistat 120 mg:</u> Dropout: 23/122 Due to adverse event: 2/122 Adverse event rate: 84%  <u>Orlistat 240 mg:</u> Dropout: 20/120 Due to adverse event: 3/120 Adverse event rate: 87%  <u>Placebo:</u> Dropout: 27/125 Due to adverse event: 3/125 Adverse event rate: 69%	Fair
-10.8 kg -7.3 kg	-3.5 kg	0.001	<u>Orlistat:</u> Dropout: 10/60 Due to adverse event: 1/60 Adverse event rate: 18/60  <u>Placebo:</u> Dropout: 10/59 Due to adverse event: NR Adverse event rate: 7/59	Fair

continue

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Study, Year	Drug Dose (mg)	Sample Size (N),		Race, Sex, Age,† Baseline BMI‡	Length, Goal	Groups
			Co-Interventions			
<b>Orlistat, continued</b>						
Rissanen et al, 2001 <sup>95</sup>	120 mg tid	D	All participants: 600 kcal deficit diet	N: 51 Race: NR Female: 100% Age: 44 yrs 36.2 kg/m <sup>2</sup>	12 mos, L	Orlistat Placebo
Broom et al, 2002 <sup>96</sup>	120 mg tid	D	All participants: mildly hypocaloric diet (minimum of 1,200 kcal/day), with food and beverage diaries	N: 531 Race: NR Female: 78% Orlistat: 46.7 yrs Placebo: 45.3 yrs Orlistat: 37.1 kg/m <sup>2</sup> Placebo: 37.0 kg/m <sup>2</sup>	54 wks, L	Orlistat Placebo
				Orlistat Placebo		
Miles et al, 2002 <sup>90</sup>	120 mg tid	D, E	All participants: recommended to increase physical activity and diet (-600 kcal/day) with dietary counseling throughout the study	N: 516 <u>Orlistat:</u> White: 84% Black: 10% Other: 6%  <u>Placebo:</u> White: 79% Black: 14% Other: 7% Female: 48%  Orlistat: 52.5 yrs Placebo: 53.7 yrs Orlistat: 35.2 kg/m <sup>2</sup> Placebo: 35.6 kg/m <sup>2</sup>	52 wks, L	Orlistat Placebo
				Orlistat Placebo		
Karhunen et al, 2000 <sup>93</sup>	120 mg tid	D	All participants: dietary advice (-600 kcal/day) individualized advice throughout the 1 yr loss phase	N: 96 Race: NR Female: 82% Age: 43 yrs 35.9 kg/m <sup>2</sup>	2 yrs: 1 yr of L 1 yr of M	Loss phase: Orlistat Placebo  Maintenance phase: (Tx Yr 1/Tx Yr 2) Orlistat/Orlistat Orlistat/Placebo Placebo/Orlistat Placebo/Placebo



**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Weight Change	Between-Group Differences§	Patients Lost		Trial Quality
		P Value	to Follow-up and Adverse Events	
-13 kg -7.2 kg	-5.8 kg	NS	Dropout: 4/55	Fair
-5.8 kg -2.3 kg <u>&gt; 5% Loss:</u> 55.6% 24.3%	-3.5 kg  31.3%	< 0.001  < 0.001	<u>Orlistat:</u> Dropout: 79/265 Due to adverse event: 20/265 Due to GI symptoms: 13/265 Serious adverse events: 13/265	Fair
<u>&gt; 10% Loss:</u> 19.7% 11.0%	8.7%	NS	<u>Placebo:</u> Dropout: 105/266 Due to adverse event: 11/266 Due to GI symptoms: 6/266 Serious adverse events: 17/266	
-4.7 kg -1.8 kg  <u>&gt; 5% Loss:</u> 39.0% 15.7%	-2.9 kg  23.3%	< 0.001  0.008	<u>Orlistat:</u> Dropout: 35% Due to adverse event: 10% Due to GI symptoms: NR GI event frequency: 83%	Fair
<u>&gt; 10% Loss:</u> 14.1% 3.9%	10.2%	0.003	<u>Placebo:</u> Dropout: 44% Due to adverse event: 5% Due to GI symptoms: NR GI event frequency: 62%	
Yr 1: -13.1 kg -8.6 kg  Yr 2 only: 3.1 kg 6.3 kg 0.5 kg 3.5 kg	-4.5 kg	0.007	No data on adverse effects Dropout: 24/96 (25%) Due to adverse event: NR	Fair

continue

Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)

Study, Year	Drug Dose (mg)	Sample Size (N), Co-Interventions	Race, Sex, Age,† Baseline BMI‡	Length, Goal	Groups
<b>Orlistat, continued</b>					
Hill et al, 1999 <sup>92</sup>	30, 60, or 120 mg 3 times daily	D, E, B All participants: 4,180 kJ/day deficit diet multi-vitamin	N: 729 White: 88 Black: 6% Hispanic: 5% Other: 1% Female: 84% <u>Orlistat:</u> 30 mg: 47 yrs 60 mg: 46 yrs  120 mg: 46 yrs <u>Placebo:</u> 46 yrs  <u>Orlistat:</u> 30 mg: 32.6 kg/m <sup>2</sup> 60 mg: 32.9 kg/m <sup>2</sup> 120 mg: 32.8 kg/m <sup>2</sup> <u>Placebo:</u> 32.8 kg/m <sup>2</sup>	52 wks M (following 6 mos of L)	Orlistat 30 mg Orlistat 60 mg Orlistat 120 mg Placebo
<b>Metformin</b>					
Giugliano et al, 1993 <sup>97</sup>	850 mg bid	Counseled to maintain baseline diet and exercise patterns	N: 50 Race: NR Female: 62%  Metformin: 60 yrs Placebo: 60.8 yrs Metformin: 33 kg/m <sup>2</sup> Placebo: 32.7 kg/m <sup>2</sup>	6 mos, L	Metformin Placebo
Knowler et al, 2002 <sup>81</sup>	850 mg bid (titrated up)	D,E Metformin and placebo participants: written information plus annual 20–30 min individual session emphasizing low-fat diet and physical activity	N: 3,234 White: 55% Black: 20% Hispanic: 16% Native American: 5% Asian: 4% Female: 68% Mean: 51 yrs 34 kg/m <sup>2</sup>	2.8 yrs, L & M	Metformin Lifestyle Placebo
<b>Multiple Drugs</b>					
Gokcel et al, 2002 <sup>98</sup>	Sibutramine: 10 mg bid Orlistat: 120 mg tid Metformin: 850 mg bid	D 25 kcal per kg of ideal body weight with caloric distribution: 50% carbohydrates 30% lipids 20% protein	N: 150 Race: NR Female: 100%  Sibutramine: 42.3 yrs Orlistat: 42.1 yrs Metformin: 43.6 yrs  Sibutramine: 38.5 kg/m <sup>2</sup> Orlistat: 35.3 kg/m <sup>2</sup> Metformin: 37.9 kg/m <sup>2</sup>	6 mos, L	Sibutramine Orlistat Metformin

**Table 3. Randomized Controlled Trials of Pharmacotherapy Interventions (cont)**

Weight Change	Between-Group Differences§	Patients Lost		to Follow-up and Adverse Events	Trial Quality
			P Value		
4.9 kg 3.8 kg 2.6 kg 4.4 kg	0.5 kg -0.6 kg -1.8 kg		< 0.001	<p><u>Orlistat 30 mg:</u> Dropout: 47/187 Due to adverse event: 17/187</p> <p><u>Orlistat 60 mg:</u> Dropout: 40/173 Due to adverse event: 17/173</p> <p><u>Orlistat 120 mg:</u> Dropout: 55/181 Due to adverse event: 27/181</p> <p><u>Placebo:</u> Dropout: 50/188 Due to adverse event: 5/188</p>	Fair
Data in graph form	Data in graph form		NS	NR	Fair
-2.1 kg -5.6 kg -0.1 kg	-2.0 kg -5.5 kg		≤ 0.001	7.5%	Good
-13.4 kg -8.0 kg -9.0 kg	-4.0 kg 1.0 kg (vs metformin)		BMI loss significantly greater with sibutramine than either other group.	<p><u>Sibutramine:</u> Dropout: NR Due to adverse event: 2/50</p> <p><u>Orlistat:</u> Dropout: NR Due to adverse event: 2/50</p> <p><u>Metformin:</u> Dropout: NR Due to adverse event: NR</p>	Fair

hemoglobin).<sup>118,120</sup> Likewise, lower diabetes incidence over 2 years (odds ratio 0.10; CI, 0.03–0.28) was seen in the SOS surgical patients versus non-surgical patients.<sup>121</sup>

## Harms of Screening and Treatment

Difficulty sustaining weight loss has raised concern that cycles of loss followed by regain potentially carry risk. Observational studies examining weight cycling and mortality show mixed results<sup>124–130</sup>; conclusions are primarily limited by failure to distinguish between intentional and unintentional weight loss. Some studies examining weight cycling with intentional weight loss have found unfavorable effects on coronary heart disease and its risk factors,<sup>131,132</sup> but others have not.<sup>133,134</sup> This literature is further limited by joint consideration of participants with diverse baseline age or weight (eg, not restricted to those with excess weight, some data suggest weight-cycling risk increases inversely with BMI, so is minimized among the obese), and measurement issues (eg, self-recalled weight and problems characterizing cycling).<sup>135–137</sup> We did not find studies or prior reviews addressing harms of screening or counseling interventions. Some risk is likely present, particularly as obesity stigma is well established.<sup>138–140</sup>

Sibutramine and orlistat both entail frequent, although typically not serious, adverse effects. Sibutramine's common side effects include insomnia, nausea, hypertension, dry mouth, dizziness, and confusion.<sup>31</sup> In the previously reviewed studies, common adverse effects occurred in 10% to 30% of sibutramine patients versus 8% to 19% of control patients.<sup>31</sup> Among recent RCTs, side effects were common (11%–79%),<sup>86–88</sup> but incidence was similar across treatments. Sibutramine's most worrisome side effects are cardiovascular, including increased blood pressure (mean, 0.0 mm Hg–3.5 mm Hg,<sup>31,86–88</sup> or 5%<sup>84,88</sup>) and heart rate (mean, 4–6.8 beats per minute [bpm]).<sup>31–33,85,87</sup> In 1 study, elevated diastolic blood pressure ( $\geq 5$  mm Hg) or pulse ( $\geq 10$  bpm) occurred in 18% more sibutramine-treated participants than controls.<sup>33</sup> In people with controlled hypertension, clinically significant blood pressure increases were similar across treatment groups,<sup>31</sup> but some individuals experienced marked

blood pressure rise.<sup>31,86</sup> When reported, dropout due to hypertension was up to 3.9% higher among those treated with sibutramine than among those not treated; overall, dropout for adverse events were similar in drug and placebo arms.<sup>84,86–88</sup>

Adverse events were reported in 7.4% to 18% more participants receiving orlistat than participants receiving placebo.<sup>31,89,91,94</sup> Most symptoms were gastrointestinal, including oily spotting, flatulence, and fecal urgency; these were reported by 22% to 95% of orlistat users (1%–37% more often than controls).<sup>89–92,96</sup> Other problems have included need for vitamin supplementation and reduced contraceptive pill absorption.<sup>31</sup> In recent trials, dropout from side effects was often more common (by 0%–12%) in orlistat-treated participants.<sup>89,90,92,94,96</sup> The metformin RCTs we reviewed did not report dropout due to drug effects; gastrointestinal symptoms were noted to be more common (77.8/100 person yrs vs 30.7/100 person yrs) in 1 trial<sup>141</sup> and present (in 4%) but transient in another. In the latter trial, mean lactic acid values did not rise.<sup>97</sup> Prior review of other weight loss medications found no evidence of serious adverse reactions for phentermine. However, case reports suggested potentially serious side effects of pulmonary hypertension with mazindol and diethylpropion therapy and psychosis with mazindol therapy.<sup>142</sup>

Because of limited surgical RCT data, we evaluated surgical adverse effects in case series reports. Adverse effects were both general (eg, need for prolonged follow-up, multivitamin supplementation) and procedure-specific. The gastric banding RCTs did not report mortality; 1 showed lower surgical complications with laparoscopic versus open procedures,<sup>100</sup> while the 2 evaluating band placement site present conflicting data regarding relative safety of esophagogastric versus gastric placement (Table 4).<sup>101,102</sup> Reported symptoms suggest low rates of dysphagia, hunger, vomiting, and esophagitis.<sup>101,102</sup> In the nonrandomized, controlled SOS study, complications were not reported by procedure; post-operative mortality was 0.2% and morbidity included bleeding (0.9%), wound complications (1.8%), abdominal infection (2.1%), thromboembolic events (0.8%),

pulmonary symptoms (6.2%), and miscellaneous events (4.8%).<sup>104</sup>

In 38 surgical case series, at least 3 (evaluating vertical banded gastroplasty and gastric bypass) included patients with substantial comorbidities<sup>143–145</sup>; multiple studies included those with modest health problems. Generally, mortality rates were low. In 12 vertical banded gastroplasty cohorts, the perioperative mortality rate ranged from 0% to 1.5% (pooled data, 6 deaths in 1,165 patients).<sup>143,145–155</sup> Similar rates were seen among gastric bypass patients (0%–1.5% per series)<sup>118,144,149,156–161</sup> and adjustable gastric banding patients (0%–1.5%).<sup>100,102,155,162–176</sup> Morbidity was more common. Vertical banded gastroplasty's main complications were reoperation (20%–25% over 3–5 yrs)<sup>148,151</sup> and wound infection (8%–32% of patients).<sup>145,148,149</sup> Less frequent events (< 6%) included gastric leaks, stomal stenosis, and pouch dilatations. In gastric bypass patients, wound infection was reported in 8% to 20%.<sup>149,159,160</sup> Single studies noted staple failure (15%),<sup>118</sup> vitamin B12 deficiency (40%),<sup>118</sup> diarrhea (13%),<sup>160</sup> and gastrointestinal hemorrhage (3%).<sup>149</sup> Adjustable gastric banding patients' morbidity was often re-operation (1%–20%),<sup>102,162,165,168–170,175,177,178</sup> band dislocation, leakage, or slippage (0.4%–8%).<sup>100,163–165,167,168,170–172,177,178</sup>

## Discussion

### Efficacy of Therapeutic Interventions for Obesity

Obesity is common and easy to screen for, poses a substantial health burden in the United States, and has treatment options. Although RCT evidence for long-term improved health with weight loss is limited, weight loss-associated changes in intermediate health variables suggest benefit. In the setting of escalating obesity prevalence, the importance of considering body weight in clinical practice seems clear.

Obese patients can achieve modest but clinically significant, sustained (1–2 yrs) weight loss (eg, 3–5 kg of weight loss) with counseling. As control groups frequently received some intervention, this estimate may be conservative. More intense programs generally achieved more success, as did those incorporating

behavioral therapy. Treating patients on an individual (vs group) basis appeared less important.

Sibutramine and orlistat have modest potentially prolonged effects (weight loss of 3–5.5 kg). These estimates do not reflect effects of lifestyle intervention that should accompany pharmacotherapy. Weight maintenance trials suggest that prolonged therapy with these drugs confers some benefit, but that its discontinuation may lead to rapid weight regain. Other drugs show inconsistent or short-term benefit. In both counseling and pharmacotherapy trials, a relatively high frequency of participants have achieved clinically significant (5%–10%) weight loss.

Surgical options can promote substantial weight loss (10–159 kg over 1–5 yrs). Case series evidence suggests such loss can be achieved in patients with multiple comorbid conditions and may be prolonged. Although surgical options are appropriate only for the very obese, between 5% and 6% of U.S. adults have a BMI of 35 or greater,<sup>179</sup> so the number of potentially eligible persons may be substantial.

### Limitations of the Literature

Limitations of prior systematic reviews included different eligibility criteria, treatment classifications, and approaches to data synthesis. In addition, aggregate values of their findings do not reflect variations in RCT sample size, length of follow-up, or treatment differences (eg, counseling intensity). There was partial, but incomplete, overlap in the literature covered by each review. Overall, however, findings were consistent.

Recent primary literature likewise had deficiencies. Among counseling and pharmacotherapy trials, internal validity was typically fair (with limitations including loss to follow-up and differential attrition between arms), although a few were judged to have good validity. Studies tended to report mean weight change but not frequency of response. External validity was an issue: participants were frequently volunteers with limited sex and ethnic diversity. No counseling RCT was of more than 54 months duration. Pharmacotherapy trials were accepted with shorter follow-up periods than other treatment modes. Although 6- and 12-month efficacy appeared similar among these trials, shorter duration could

Table 4. Randomized Controlled Trials of Surgical Interventions

Study, Year	Goal	Sample Size (N), Race, Sex, and Age	Co-Intervention	Baseline BMI† (mean kg/m <sup>2</sup> )	Duration
de Wit et al, 2002 <sup>100</sup>	L	N: 50 Race: NR Female: 68%	NR	51.3 (laparoscopic) 49.7 (open)	1 yr
Weiner et al, 2001 <sup>102</sup>	L	N: 101 Race: NR Female: 85%	"Interdisciplinary obesity surgery program"	49.5 (esophagogastric) 48.5 (retrogastric)	18 mos
Weiss et al, 2002 <sup>101</sup>	L	N: 52 Race: NR Female: 90%	NR	42.5 (gastric) 41.8 (esophagogastric)	23–24 mos

ASGB, adjustable silicone gastric banding; L, weight loss; NR, not reported.

† Presented as baseline mean or range unless otherwise noted.

**Table 4. Randomized Controlled Trials of Surgical Interventions (cont)**

Groups	Weight Change	Between-Group Difference	P Value	Patients Lost to Follow-up and Adverse Events	Trial Quality
ASGB: Laparoscopic Open	-35.0 kg -34.4 kg	-1.4 kg	NS	Loss to follow-up: 2% <u>Surgical complications</u> Laparoscopic: 0% Open: 16.7% (incisional hernias, migrating band) <u>Access port complications</u> Laparoscopic: 20% Open: 21% <u>Mean hospital stay (days)</u> Laparoscopic: 7.8 Open: 11.8 <u>Patients with readmission</u> Laparoscopic: 20% Open: 29%	Fair
Placement of laparoscopic ASGB: Esophagogastric Retrogastric	Data in graph form: > 40 kg loss in both groups	NR	NS	Loss to follow-up: 4% <u>Band slippage</u> Esophagogastric: 0% Retrogastric: 2% <u>Pouch dilation</u> Esophagogastric: 0% Retrograde: 6% <u>Esophageal dilation</u> Esophagogastric: 4% Retrograde: 4% <u>Hunger at 18 mos</u> Esophagogastric: 2% Retrograde: 4% <u>Dysphagia at 18 mos</u> Esophagogastric: 2% Retrograde: 2% <u>Recurrent vomiting at 18 mo</u> Esophagogastric: 2% Retrograde: 2% <u>Esophagitis at 18 mos</u> Esophagogastric: 2% Retrograde: 2%	Fair
Placement of laparoscopic ASGB:  Gastric Esophagogastric  Gastric Esophagogastric  Gastric Esophagogastric	Median BMI  -17.4 kg/m <sup>2</sup> -18.9 kg/m <sup>2</sup>  25% loss 100% 100%  Gain 0% 0%	  1.5 kg/m <sup>2</sup>  0%  0%	NS	Loss to follow-up: NR Mortality: NR <u>Conversion to open surgery</u> Gastric: 3.6% Esophagogastric: 3.8% <u>Need for reoperation</u> Gastric: 10.7% Esophagogastric: 19.2% <u>Heartburn at 2 yrs</u> Gastric: 11.1% Esophagogastric: 14.3% <u>Dysphagia at 2 yrs</u> Gastric: 0% Esophagogastric: 57.1%	Fair

inflate estimates of sustained weight loss. Surgical data were limited by lack of placebo-controlled RCT evidence; available studies often did not report response frequency, participant comorbidities, or co-interventions.

Finally, some studies (particularly pharmacotherapy ones) used a “last observation carried forward” analytic approach—the final weight outcome available was used as the final weight for those participants who dropped out of the study. Because maximal weight loss tends to occur within 6 months of intervention, this technique may overestimate the ability to sustain weight loss. Although a common technique when a true intention-to-treat analysis is not possible, it should be combined with alternate analyses.<sup>180,181</sup> Although many trials showed parallel analyses of trial enrollees and completers, few authors presented parallel “worst case” analyses.

## Harms of Intervention

Treatment appeared reasonably safe. We identified no evidence evaluating counseling harms. Both sibutramine and orlistat had clinically significant, often mild, adverse effects in trials lasting, at most, 2 years. Surgical options clearly entail the highest risk; they lead to mortality in less than 1% of patients in pooled samples, but up to 25% of patients may need re-operation over 5 years.

A systematic review of intervention costs was beyond the scope of this project, but, notably, obesity treatment options may entail considerable cost. Intensive counseling programs require significant time and staffing commitment. Based on average U.S. wholesale price, a 1-year supply of orlistat (120 mg 3 times daily) is \$1,445.40 and sibutramine (15 mg daily) is \$1464.78.<sup>182</sup> Surgical costs reflect both the invasive procedure and long-term follow-up. Potentially, long-term health improvements may offset these costs to some extent.

## Implications for Clinical Practice and Research

Most efficacy trials reviewed here were not carried out in clinical settings; some interventions, particularly intense counseling, may be difficult to incorporate into medical practice. One option may

be referral to programs that offer intense counseling with behavioral therapy. Another may be combining office-based counseling with innovative delivery of behavioral approaches, such as video tapes or Internet-delivered adjuncts.

Other topics requiring future research include longer-term efficacy and harms follow-up of weight loss strategies (including better characterization of weight-cycling risks), post marketing safety records of drugs, ability of interventions to alter body fat distribution, race- and ethnic-specific health effects of purposeful reduction of central adiposity, and efficacy of weight maintenance strategies. In the interest of obesity prevention, treatment efficacy and health effects of lifestyle modification should be clarified for patients who are overweight, but not obese. Finally, better estimates of the cost-effectiveness of obesity screening and treatment, including their impact on long-term health outcomes, are needed.

Long-term research on combined treatment modalities in more generalized populations is needed. We were unable to assess treatment effectiveness by sex or ethnicity. Intervention efficacy trials have focused on white women, and observational evidence for health outcomes comes mostly from populations of European origin. Treatment efficacy may differ with race<sup>11,78</sup>; as certain ethnic groups have a disproportionate obesity prevalence, this area needs further attention.

All obesity therapies carry promise and burden, which must be balanced in clinical decision-making. Counseling approaches appear the least harmful and produce modest, clinically important weight loss, but entail cost in time and resources. Pharmacotherapy promotes modest additional weight loss, but long-term drug use may be needed to sustain this benefit with unknown long-term adverse events and appreciable cost. Only surgical options consistently result in large amounts of long-term weight reduction; however, they carry a low risk for severe complications and are expensive. Body size, health status, and prior weight loss history may all influence obesity treatment.



## Acknowledgments

The authors thank David Atkins, MD, MPH, Medical Officer, Center for Outcomes and Evidence, and Eve Shapiro, Managing Editor, USPSTF, AHRQ. We extend our appreciation as well to Loraine Monroe of RTI.

This study was developed by the RTI International–University of North Carolina Evidence-based Practice Center under contract to the AHRQ (Contract No. 290-97-0011), Rockville, Maryland. Dr. McTigue was supported by the University of North Carolina Robert Wood Johnson Clinical Scholars Program.

## References

1. National Center for Health Statistics Division of Data Services. Health, United States 2002, with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics, Division of Data Services; 2002.
2. Dietz WH. Overweight and precursors of type 2 diabetes mellitus in children and adolescents. *J Pediatr*. 2001;138:453–454.
3. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986–1998. *JAMA*. 2001;286:2845–2848.
4. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999–2000. *JAMA*. 2002;288:1728–1732.
5. National Center for Health Statistics. Health, United States, 2001. With Urban and Rural Health Chartbook, Hyattsville, MD: National Center for Health Statistics; 2001.
6. Harwell TS, Gohdes D, Moore K, McDowall JM, Smilie JG, Helgerson SD. Cardiovascular disease and risk factors in Montana American Indians and non-Indians. *Am J Prev Med*. 2001;20:196–201.
7. U.S. Preventive Services Task Force. *Guide to Clinical Preventive Services*. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996:219–229.
8. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. *JAMA*. 2003;289:187–193.
9. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. *Ann Intern Med*. 2003;138:24–32.
10. Roe DA, Eickwort KR. Relationships between obesity and associated health factors with unemployment among low income women. *J Am Med Womens Assoc*. 1976;31:193–194, 198–199, 203–204.
11. NHLBI Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Bethesda, MD. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute. 1998; NIH Publication No. 98-4083.
12. McTigue KM, Garrett JM, Popkin BM. The natural history of the development of obesity in a cohort of young U.S. adults between 1981 and 1998. *Ann Intern Med*. 2002;136:857–864.
13. Juhaeri, Stevens J, Chambless LE, et al. Associations between weight gain and incident hypertension in a bi-ethnic cohort: the Atherosclerosis Risk in Communities Study. *Int J Obes Relat Metab Disord*. 2002;26:58–64.
14. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. *Metabolism*. 1996;45:1119–1124.
15. Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. *Diabetes*. 1997;46:456–462.
16. Casas YG, Schiller BC, DeSouza CA, Seals DR. Total and regional body composition across age in healthy Hispanic and white women of similar socioeconomic status. *Am J Clin Nutr*. 2001;73:13–18.
17. Conway JM, Yanovski SZ, Avila NA, Hubbard VS. Visceral adipose tissue differences in black and white women. *Am J Clin Nutr*. 1995;61:765–771.
18. Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of upper body obesity. *Diabetes*. 1993;42:537–543.
19. Lear SA, Chen MM, Frohlich JJ, Birmingham CL. The relationship between waist circumference and

- metabolic risk factors: cohorts of European and Chinese descent. *Metabolism*. 2002;51:1427–1432.
20. Wajchenberg BL, Giannella-Neto D, Da Silva ME, Santos RF. Depot-Specific Hormonal Characteristics of Subcutaneous and Visceral Adipose Tissue and their Relation to the Metabolic Syndrome. *Horm Metab Res*. 2002;34:616–621.
  21. Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. *Obes Res*. 2001;9:381–387.
  22. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. *Am J Clin Nutr*. 1999;69:381–387.
  23. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. *J Clin Endocrinol Metab*. 2003;88:2534–2540.
  24. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. *Obes Res*. 1998;6:97–106.
  25. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. *Arch Intern Med*. 1999;159:2177–2183.
  26. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? *JAMA*. 1999;282:1576–1578.
  27. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. *Am J Prev Med*. 2001;20 (3 Suppl):21–35.
  28. Douketis JD, Feightner JW, Attia J, Feldman WF. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care. *CMAJ*. 1999;160:513–525.
  29. NHS Centre for Reviews and Dissemination University of York. The prevention and treatment of obesity. *Eff Health Care*. 1997;3:1–12.
  30. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. *JAMA*. 1996;276:1907–1915.
  31. Arterburn D, Noel PH. Effects of drug treatment for obesity in adults. *Clin Evid*. 2001;412–419.
  32. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. *Diabetes Care*. 2001;24:1957–1960.
  33. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. *Diabetes Care*. 2003;26:125–131.
  34. Sorkin JD, Muller D, Andres R. Body mass index and mortality in Seventh-day Adventist men. A critique and re-analysis. *Int J Obes Relat Metab Disord*. 1994;18:752–754.
  35. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. *N Engl J Med*. 1995;333:677–685.
  36. Laara E, Rantakallio P. Body size and mortality in women: a 29 year follow up of 12,000 pregnant women in northern Finland. *J Epidemiol Community Health*. 1996;50:408–414.
  37. Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. *BMJ*. 1997;314:1311–1317.
  38. Chyou PH, Burchfiel CM, Yano K, et al. Obesity, alcohol consumption, smoking, and mortality. *Ann Epidemiol*. 1997;7:311–317.
  39. Wannamethee SG, Shaper AG, Walker M, Ebrahim S. Lifestyle and 15-year survival free of heart attack, stroke, and diabetes in middle-aged British men. *Arch Intern Med*. 1998;158:2433–2440.
  40. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. *Ann Intern Med*. 1998;128:81–88.
  41. Durazo-Arvizu RA, McGee DL, Cooper RS, Liao Y, Luke A. Mortality and optimal body mass index in a sample of the US population. *Am J Epidemiol*. 1998;147:739–749.
  42. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a

- prospective cohort of U.S. adults. *N Engl J Med*. 1999;341:1097–1105.
43. Rosengren A, Wedel H, Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study. *Eur Heart J*. 1999;20:269–277.
  44. Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. *Arch Intern Med*. 2000;160:2117–2128.
  45. Song YM, Sung J. Body mass index and mortality: a twelve-year prospective study in Korea. *Epidemiology*. 2001;12:173–179.
  46. Allison DB, Moonseong H, Fontaine KR, Hoffman DJ. Body weight, body composition and longevity. In: Bojorntorp P, ed. *International Textbook of Obesity*. New York: J Wiley; 2001:31–48.
  47. Kim KS, Owen WL, Williams D, Adams-Campbell LL. A comparison between BMI and Conicity index on predicting coronary heart disease: the Framingham Heart Study. *Ann Epidemiol*. 2000;10:424–431.
  48. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *Br J Cancer*. 2001;84:417–422.
  49. Stevens J. Obesity and mortality in African-Americans. *Nutr Rev*. 2000;58(11):346–353.
  50. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. *Arch Intern Med*. 2001;161:1194–1203.
  51. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. *Br J Nutr*. 1991;65:105–114.
  52. Gray DS, Fujioka K. Use of relative weight and Body Mass Index for the determination of adiposity. *J Clin Epidemiol*. 1991;44:545–550.
  53. Wang J, Thornton JC, Russell M, Burastero S, Heymsfield S, Pierson RN Jr. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. *Am J Clin Nutr*. 1994;60:23–28.
  54. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. *Int J Obes Relat Metab Disord*. 1998;22:1164–1171.
  55. Gurruci S, Hartriyanti Y, Hautvast JG, Deurenberg P. Relationship between body fat and body mass index: differences between Indonesians and Dutch Caucasians. *Eur J Clin Nutr*. 1998;52:779–783.
  56. Deurenberg P, van der Kooy K, Hulshof T, Evers P. Body mass index as a measure of body fatness in the elderly. *Eur J Clin Nutr*. 1989;43:231–236.
  57. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Intern Med*. 1995;122:481–486.
  58. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. *JAMA*. 1998;280:1843–1848.
  59. Liese AD, Mayer-Davis EJ, Tyroler HA, et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. *Ann Epidemiol*. 1997;7:407–416.
  60. Baik I, Ascherio A, Rimm EB, et al. Adiposity and mortality in men. *Am J Epidemiol*. 2000;152:264–271.
  61. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. *Arch Intern Med*. 2002;162:2074–2079.
  62. Eden KB, Orleans CT, Mulrow CD, Pender NJ, Teutsch SM. Does counseling by clinicians improve physical activity? A summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2002;137:208–215.
  63. U.S. Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996. Available at: <http://www.cdc.gov/nccdphp/sgr/pdf/sgrfull.pdf>. Accessed July 23, 2003.
  64. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women

- in the lipid research clinics study. *Am J Epidemiol*. 2002;156:832–841.
65. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. *Arch Intern Med*. 2001;161:218–227.
  66. Kuller LH, Simkin-Silverman LR, Wing RR, Meilahn EN, Ives DG. Women's Healthy Lifestyle Project: A randomized clinical trial: results at 54 months. *Circulation*. 2001;103:32–37.
  67. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344:1343–1350.
  68. Rothacker DQ, Staniszewski BA, Ellis PK. Liquid meal replacement vs traditional food: a potential model for women who cannot maintain eating habit change. *J Am Diet Assoc*. 2001;101:345–347.
  69. Jones DW, Miller ME, Wofford MR, et al. The effect of weight loss intervention on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) study. *Am J Hypertens*. 1999;12:1175–1180.
  70. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Ann Intern Med*. 2001;134:1–11.
  71. Swinburn BA, Woollard GA, Chang EC, Wilson MR. Effects of reduced-fat diets consumed ad libitum on intake of nutrients, particularly antioxidant vitamins. *J Am Diet Assoc*. 1999;99:1400–1405.
  72. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. *JAMA*. 1999;282:1554–1560.
  73. Leermakers EA, Perri MG, Shigaki CL, Fuller PR. Effects of exercise-focused versus weight-focused maintenance programs on the management of obesity. *Addict Behav*. 1999;24:219–227.
  74. Sbrocco T, Nedegaard RC, Stone JM, Lewis EL. Behavioral choice treatment promotes continuing weight loss: preliminary results of a cognitive-behavioral decision-based treatment for obesity. *J Consult Clin Psychol*. 1999;67:260–266.
  75. Fogelholm M, Kukkonen-Harjula K, Oja P. Eating control and physical activity as determinants of short-term weight maintenance after a very-low-calorie diet among obese women. *Int J Obes Relat Metab Disord*. 1999;23:203–210.
  76. Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M. Effects of walking training on weight maintenance after a very-low-energy diet in premenopausal obese women: a randomized controlled trial. *Arch Intern Med*. 2000;160:2177–2184.
  77. Jeffery RW, French SA. Preventing weight gain in adults: design, methods and one year results from the Pound of Prevention study. *Int J Obes Relat Metab Disord*. 1997;21:457–464.
  78. Wing RR, Anglin K. Effectiveness of a behavioral weight control program for blacks and whites with NIDDM. *Diabetes Care*. 1996;19:409–413.
  79. Lindholm LH, Ekblom T, Dash C, Eriksson M, Tibblin G, Schersten B. The impact of health care advice given in primary care on cardiovascular risk. CELL Study Group. *BMJ*. 1995;310:1105–1109.
  80. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. *BMJ*. 1995;310:1099–1104.
  81. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393–403.
  82. Ashley JM, St Jeor ST, Schrage JP, et al. Weight control in the physician's office. *Arch Intern Med*. 2001;161:1599–1604.
  83. Bemelmans WJ, Broer J, de Vries JH, Hulshof KF, May JF, Meyboom-De Jong B. Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. *Public Health Nutr*. 2000;3:273–283.
  84. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. *Lancet*. 2000;356:2119–2125.

85. Dujovne CA, Zavoral JH, Rowe E, Mendel CM; The Sibutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. *Am Heart J*. 2001;142:489–497.
86. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2000;2:175–187.
87. Smith IG, Goulder MA; On behalf of the Members of the Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. *J Fam Pract*. 2001;50:505–512.
88. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. *JAMA*. 2001;286:1331–1339.
89. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. *Eur J Clin Pharmacol*. 1998;54:125–132.
90. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. *Diabetes Care*. 2002;25:1123–1128.
91. Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. *Int J Obes*. 2001;25:1713–1721.
92. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. *Am J Clin Nutr*. 1999;69:1108–1116.
93. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. *Int J Obes Relat Metab Disord*. 2000;24:1567–1572.
94. Micic D, Ivkovic-Lazar T, Dragojevic R, Jorga J, Stokic E, Hajdukovic Z. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. *Med Pregl*. 1999;52:323–333.
95. Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. *Int J Obes Relat Metab Disord*. 2001;25:212–218.
96. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. *Int J Clin Pract*. 2002;56:494–499.
97. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. *Eur J Clin Pharmacol*. 1993;44:107–112.
98. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. *Diabetes Obes Metab*. 2002;4:49–55.
99. Hubbard VS, Hall WH. Gastrointestinal surgery for severe obesity. *Obes Surg*. 1991;1(3):257–265.
100. de Wit LT, Mathus-Vliegen L, Hey C, Rademaker B, Gouma DJ, Obertop H. Open versus laparoscopic adjustable silicone gastric banding: a prospective randomized trial for treatment of morbid obesity. *Ann Surg*. 1999;230:800–805; discussion 805–807.
101. Weiss HG, Nehoda H, Labeck B, et al. Adjustable gastric and esophagogastric banding: a randomized clinical trial. *Obes Surg*. 2002;12:573–578.
102. Weiner R, Bockhorn H, Rosenthal R, Wagner D. A prospective randomized trial of different laparoscopic gastric banding techniques for morbid obesity. *Surg Endosc*. 2001;15:63–68.
103. Sjostrom L, Larsson B, Backman L, et al. Swedish Obese Subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. *Int J Obes Relat Metab Disord*. 1992;16:465–479.
104. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study—rationale and results. *Int J Obes Relat Metab Disord*. 2001;25(Suppl 1):S2–S4.
105. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year,

- double-blind, placebo-controlled, multicenter trial. *Arch Intern Med.* 2000;160:2185–2191.
106. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. *Lancet.* 1998;352:167–172.
  107. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. *Diabetes Care.* 1998;21:1288–1294.
  108. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. *J Intern Med.* 2000;248:245–254.
  109. Rossner S, Sjostrom L, Noack R, Meinders AE, Nosedá G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. *Obes Res.* 2000;8:49–61.
  110. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med.* 2000;9:160–167.
  111. Scheen AJ, Lefebvre PJ. Pharmacological treatment of obesity: present status. *Int J Obes Relat Metab Disord.* 1999;23(Suppl 1):47–53.
  112. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. *Ann Pharmacother.* 1999;33:968–978.
  113. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. *Am J Med.* 1999;106:179–184.
  114. Bray GA. Drug treatment of obesity. *Baillieres Best Pract Res Clin Endocrinol Metab.* 1999;13:131–148.
  115. Orlistat. No hurry.... *Can Fam Physician.* 1999; 45:2331–2333, 2336–2338, 2343–2345 passim.
  116. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. *Int J Obes Relat Metab Disord.* 2000;24:306–313.
  117. Sjostrom L. Surgical intervention as a strategy for treatment of obesity. *Endocrine Journal-Uk.* 2000;13:213–230.
  118. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. *Ann Surg.* 1995;222:339–350; discussion 350–352.
  119. Brodin RE, Bradley LJ, Wilson AC, Cody RP. Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. *J Gastrointest Surg.* 2000;4:464–469.
  120. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res.* 1999;7:477–484.
  121. Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. *Obes Res.* 2001;9:188–195.
  122. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. *Am J Epidemiol.* 1995;141:1128–1141.
  123. Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. *Br Med J.* 1992;304:1015–1019.
  124. Lissner L, Odell PM, D’Agostino RB, et al. Variability of body weight and health outcomes in the Framingham population. *N Engl J Med.* 1991;324:1839–1844.
  125. Blair SN, Shaten J, Brownell K, Collins G, Lissner L. Body weight change, all-cause mortality, and cause-specific mortality in the Multiple Risk Factor Intervention Trial. *Ann Intern Med.* 1993;119:749–757.
  126. Andres R, Muller DC, Sorkin JD. Long-term effects of change in body weight on all-cause mortality. A review. *Ann Intern Med.* 1993;119:737–743.
  127. Williamson DF. “Weight cycling” and mortality: how do the epidemiologists explain the role of

- intentional weight loss? *J Am Coll Nutr.* 1996;15:6–13.
128. Reynolds MW, Fredman L, Langenberg P, Magaziner J. Weight, weight change, mortality in a random sample of older community-dwelling women. *J Am Geriatr Soc.* 1999;47:1409–1414.
129. Williamson DF, Pamuk ER. The association between weight loss and increased longevity. A review of the evidence. *Ann Intern Med.* 1993;119:731–736.
130. National Task Force on the Prevention and Treatment of Obesity. Weight cycling. *JAMA.* 1994;272:1196–1202.
131. Olson MB, Kelsey SF, Bittner V, et al. Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group. *J Am Coll Cardiol.* 2000;36:1565–1571.
132. Guagnano MT, Ballone E, Pace-Palitti V, et al. Risk factors for hypertension in obese women. The role of weight cycling. *Eur J Clin Nutr.* 2000;54:356–360.
133. Field AE, Wing RR, Manson JE, Spiegelman DL, Willett WC. Relationship of a large weight loss to long-term weight change among young and middle-aged US women. *Int J Obes Relat Metab Disord.* 2001;25:1113–1121.
134. Petersmarck KA, Teitelbaum HS, Bond JT, Bianchi L, Hoerr SM, Sowers MF. The effect of weight cycling on blood lipids and blood pressure in the Multiple Risk Factor Intervention Trial Special Intervention Group. *Int J Obes Relat Metab Disord.* 1999;23:1246–1255.
135. Bouchard C. Is weight fluctuation a risk factor? *N Engl J Med.* 1991;324:1887–1889.
136. Kuller L, Wing R. Weight loss and mortality. *Ann Intern Med.* 1993;119:630–632.
137. Dellinger E. Variability of body weight and health outcomes (ed). *N Engl J Med.* 1997;325:1745–1746.
138. Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH. Social and economic consequences of overweight in adolescence and young adulthood. *N Engl J Med.* 1993;329:1008–1012.
139. Teachman BA, Brownell KD. Implicit anti-fat bias among health professionals: is anyone immune? *Int J Obes Relat Metab Disord.* 2001;25:1525–1531.
140. Myers A, Rosen JC. Obesity stigmatization and coping: relation to mental health symptoms, body image, and self-esteem. *Int J Obes Relat Metab Disord.* 1999;23:221–230.
141. Knowler WC, Narayan KM, Hanson RL, et al. Preventing non-insulin-dependent diabetes. *Diabetes.* 1995;44:483–488.
142. Arterburn D, Noel PH. Extracts from “Clinical Evidence” Obesity. *BMJ.* 2001;322:1406–1409.
143. Melissas J, Christodoulakis M, Spyridakis M, et al. Disorders associated with clinically severe obesity: significant improvement after surgical weight reduction. *South Med J.* 1998;91:1143–1148.
144. Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. *Ann Surg.* 2000;232:515–529.
145. Bloomston M, Zervos EE, Camps MA, Goode SE, Rosemurgy AS. Outcome following bariatric surgery in super versus morbidly obese patients: does weight matter? *Obes Surg.* 1997;7:414–419.
146. Balsiger BM, Poggio JL, Mai J, Kelly KA, Sarr MG. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. *J Gastrointest Surg.* 2000;4:598–605.
147. Davila-Cervantes A, Ganci-Cerrud G, Gamino R, Gallegos-Martinez J, Gonzalez-Barranco J, Herrera MF. Open vs. laparoscopic vertical banded gastroplasty: a case control study with a 1-year follow-up. *Obes Surg.* 2000;10:409–412.
148. Alper D, Ramadan E, Vishne T, et al. Silastic ring vertical gastroplasty—long-term results and complications. *Obes Surg.* 2000;10:250–254.
149. Choi Y, Frizzi J, Foley A, Harkabus M. Patient satisfaction and results of vertical banded gastroplasty and gastric bypass. *Obes Surg.* 1999;9:33–35.
150. Papakonstantinou A, Alfaras P, Komessidou V, Hadjiyannakis E. Gastrointestinal complications after vertical banded gastroplasty. *Obes Surg.* 1998;8:215–217.

151. Baltasar A, Bou R, Arlandis F, et al. Vertical banded gastroplasty at more than 5 years. *Obes Surg.* 1998;8:29–34.
152. Stoner J, Stoner P, Sytsma J. 42-month preliminary follow-up of the silastic ring vertical banded gastroplasty. *Obes Surg.* 1997;7:513–515.
153. Yashkov YI, Timoshin AD, Opperl TA. Vertical banded gastroplasty: first experience in Russia. *Obes Surg.* 1997;7:317–320; discussion 321.
154. Goulding ST, Hovell BC. Anaesthetic experience of vertical banded gastroplasty. *Br J Anaesth.* 1995;75:301–306.
155. Lundell L, Ruth M, Olbe L. Vertical banded gastroplasty or gastric banding for morbid obesity: effects on gastro-oesophageal reflux. *Eur J Surg.* 1997;163:525–531.
156. Nguyen NT, Ho HS, Palmer LS, Wolfe BM. A comparison study of laparoscopic versus open gastric bypass for morbid obesity. *J Am Coll Surg.* 2000;191:149–155; discussion 155–157.
157. Choban PS, Onyjekwe J, Burge JC, Flancbaum L. A health status assessment of the impact of weight loss following Roux-en-Y gastric bypass for clinically severe obesity. *J Am Coll Surg.* 1999;188:491–497.
158. Jones KB. Roux-en-Y gastric bypass: an effective antireflux procedure in the less than morbidly obese. *Obes Surg.* 1998;8:35–38.
159. Crampton NA, Izvornikov V, Stubbs RS. Silastic ring gastric bypass: results in 64 patients. *Obes Surg.* 1997;7:489–494.
160. Freeman JB, Kotlarewsky M, Phoenix C. Weight loss after extended gastric bypass. *Obes Surg.* 1997;7:337–344.
161. Oh CH, Kim HJ, Oh S. Weight loss following transected gastric bypass with proximal Roux-en-Y. *Obes Surg.* 1997;7:142–147; discussion 148.
162. Abu-Abeid S, Szold A. Laparoscopic management of Lap-Band erosion. *Obes Surg.* 2001;11:87–89.
163. Nowara HA. Egyptian experience in laparoscopic adjustable gastric banding (technique, complications and intermediate results). *Obes Surg.* 2001;11:70–75.
164. De Luca M, de Werra C, Formato A, et al. Laparotomic vs laparoscopic lap-band: 4-year results with early and intermediate complications. *Obes Surg.* 2000;10:266–268.
165. Suter M, Bettschart V, Giusti V, Heraief E, Jayet A. A 3-year experience with laparoscopic gastric banding for obesity. *Surg Endosc.* 2000;14:532–536.
166. Wiesner W, Schob O, Hauser RS, Hauser M. Adjustable laparoscopic gastric banding in patients with morbid obesity: radiographic management, results, and postoperative complications. *Radiology.* 2000;216:389–394.
167. Holeczy P, Novak P, Kralova A. Complications in the first year of laparoscopic gastric banding: is it acceptable? *Obes Surg.* 1999;9:453–455.
168. Dargent J. Laparoscopic adjustable gastric banding: lessons from the first 500 patients in a single institution. *Obes Surg.* 1999;9:446–452.
169. Suter M, Giusti V, Heraief E, Jayet C, Jayet A. Early results of laparoscopic gastric banding compared with open vertical banded gastroplasty. *Obes Surg.* 1999;9:374–380.
170. Abu-Abeid S, Szold A. Results and complications of laparoscopic adjustable gastric banding: an early and intermediate experience. *Obes Surg.* 1999;9:188–190.
171. Miller K, Hell E. Laparoscopic adjustable gastric banding: a prospective 4-year follow-up study. *Obes Surg.* 1999;9:183–187.
172. Forsell P, Hallerback B, Glise H, Hellers G. Complications following Swedish adjustable gastric banding: a long-term follow-up. *Obes Surg.* 1999;9:11–16.
173. Doherty C, Maher JW, Heitshusen DS. Prospective investigation of complications, reoperations, and sustained weight loss with an adjustable gastric banding device for treatment of morbid obesity. *J Gastrointest Surg.* 1998;2:102–108.
174. Forestieri P, Meucci L, De Luca M, Formato A, De Werra C, Chiacchio C. Two years of practice in adjustable silicone gastric banding (LAP-BAND): evaluation of variations of body mass index, percentage ideal body weight and percentage excess body weight. *Obes Surg.* 1998;8:49–52.
175. Forsell P, Hellers G. The Swedish Adjustable Gastric Banding (SAGB) for morbid obesity: 9 year experience and a 4-year follow-up of patients



- operated with a new adjustable band. *Obes Surg.* 1997;7:345–351.
176. Horchner R, Tuinebreijer W. Improvement of physical functioning of morbidly obese patients who have undergone a Lap-Band operation: one-year study. *Obes Surg.* 1999;9:399–402.
177. Doldi SB, Micheletto G, Lattuada E, Zappa MA, Bona D, Sonvico U. Adjustable gastric banding: 5-year experience. *Obes Surg.* 2000;10:171–173.
178. Weiner R, Datz M, Wagner D, Bockhorn H. Quality-of-life outcome after laparoscopic adjustable gastric banding for morbid obesity. *Obes Res.* 1999;9:539–545.
179. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA.* 1999;282:1523–1529.
180. Friedman LM, Furberg CD, DeMets DL. *Fundamentals of Clinical Trials.* 3rd ed. New York: Springer; 1998.
181. Jadad A. *Randomized Controlled Trials.* London: BMJ Books; 1998.
182. *2002 Drug Topics Red Book: The Pharmacist's Trusted Companion for More Than a Century.* Montvale, NJ: Medical Economics Company; 2002.

# Appendix

Appendix Table 1. Screening for Obesity: Eligibility Criteria and Results of Searches		
Key Question	Eligibility Criteria	Number of Articles Meeting Eligibility Criteria and Not in Prior Systematic Review†
Efficacy of screening	RCT Mass screening	0
Epidemiology of obesity		
a. Prevalence	Large U.S. population-based surveys	1
b. Health risks	Prospective cohort studies with absolute rates of health risk reported over ≥ 10 yrs	14
Efficacy of treatment for weight reduction or intermediate outcomes		
a. Counseling and behavioral treatment	<ul style="list-style-type: none"> <li>— RCT (of fair or good quality)</li> <li>— Outcome: weight loss or BMI reduction; glucose tolerance, blood pressure, lipid disorders</li> <li>— Duration: ≥ 1 yr</li> <li>— BMI ≥ 25 kg/m<sup>2</sup></li> <li>— 12-mo follow-up</li> </ul>	21
b. Medications	<ul style="list-style-type: none"> <li>— RCT (of fair or good quality)</li> <li>— Outcome: weight loss or BMI reduction; glucose tolerance, blood pressure, lipid disorders</li> <li>— Duration: ≥ 6 mos</li> <li>— Population: generalizable to typical U.S. primary care population</li> </ul>	10
c. Surgery	<ul style="list-style-type: none"> <li>— RCT (of fair or good quality)</li> <li>— Outcome: weight loss or BMI reduction; glucose tolerance, blood pressure, lipid disorders</li> <li>— Duration: ≥ 1 yr</li> <li>— Cohort</li> <li>— Initial BMI ≥ 25 kg/m<sup>2</sup></li> <li>— Surgical procedure</li> </ul>	2
Harms of screening and treatment	Same studies as efficacy of counseling/behavioral and medication interventions For surgery, same studies as efficacy plus multiple cohorts and 1 non-RCT	21 counseling 15 medication 2 surgery

RCT, randomized controlled trial; BMI, body mass index.

† References 11, 28, 29, 31.

**Appendix Table 2. Criteria for Grading the Internal Validity of Individual Studies\***

<b>Study Design</b>	<b>Criteria</b>
Systematic reviews	Comprehensiveness of sources and search strategy used Standard appraisal of included studies Validity of conclusions Recency and relevance
Case-control studies	Accurate ascertainment of cases Nonbiased selection of cases and controls with exclusion criteria applied equally to both Response rate Diagnostic testing procedures applied equally to each group Appropriate attention to potential confounding variables
Randomized controlled trials (RCTs) and cohort studies	Initial assembly of comparable groups: For RCTs: adequate randomization, including concealment and whether potential confounders were distributed equally among groups For cohort studies: consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts Maintenance of comparable groups (includes attrition, crossovers, adherence, contamination) Important differential loss to follow-up or overall high loss to follow-up Measurements: equal, reliable, and valid (includes masking of outcome assessment) Clear definition of interventions All important outcomes considered Analysis: adjustment for potential confounders for cohort studies, or intention-to-treat analysis for RCTs
Diagnostic accuracy studies	Screening test relevant, available for primary care, adequately described Study uses a credible reference standard, performed regardless of test results Reference standard interpreted independently of screening test Handles indeterminate results in a reasonable manner Spectrum of patients included in study Sample size Administration of reliable screening test

\* Based on reference 27.

**Appendix Table 3. Intensive Counseling Intervention Descriptions†**

<b>Study, Year</b>	<b>Intervention</b>	<b>Intervention Setting</b>	<b>Intervention Delivery</b>
Stevens et al, 2001 <sup>70</sup>	Control	Not noted	Not noted
	Weight loss only	Not noted	Dietitians or health educators
Knowler et al, 2002 <sup>81</sup>	Standard lifestyle + placebo	Not noted	Not noted
	Standard lifestyle + metformin	Not noted	Not noted
	Intensive lifestyle	Not noted	Case managers
Kuller et al, 2001 <sup>66</sup>	Assessment only	Large research clinic	Psychologists (PhD level)
	Lifestyle intervention	Large research clinic	Psychologists (PhD level), nutritionists, exercise physiologists
Tuomilehto et al, 2001 <sup>67</sup>	Control	Not noted	Not noted
	Intervention	Not noted	Nutritionist

LCD, low calorie diet; LDL, low-density lipoprotein; VLCD, very low calorie diet; USDA, U.S. Department of Agriculture.

† Information was primarily obtained from the published sources listed. In selected cases (Tuomilehto et al,<sup>67</sup> Kuller et al<sup>66</sup>), additional information was obtained from study staff.

**Appendix Table 3. Intensive Counseling Intervention Descriptions† (cont)**

**Counseling and Behavioral Description**

Usual care (details not noted)

One individual counseling session, then 14 weekly group meetings, then 6 biweekly group meetings, then monthly group meetings. After 18 mos, alternative options were offered, including individual counseling and special group sessions focused on selected weight loss topics. Focus included self-directed behavior change, nutrition and physical activity education, and social support for making and maintaining behavior changes. Behavior change techniques included self-monitoring, setting explicit short-term goals, developing action plans to achieve those objectives, and alternative strategies for situations triggering problem eating. Dietary intervention focused on reduced calorie intake by less consumption of fat, sugar, and alcohol, with a minimum daily caloric intake of 1,500 kcal for men and 1,200 kcal for women, and moderate weight loss goals of  $\leq 0.9$  kg/wk. Physical activity goal was for gradually increased activity to moderate-intensity activity (40%–55% of heart rate reserve) 30–45 mins/day, 4–5 days/wk. Primary exercise was brisk walking.

Written information and an annual 20–30 minute individual session emphasizing importance of healthy lifestyles. Advice included encouragement to follow the USDA Food Guide Pyramid and equivalent of National Cholesterol Education Program Step I diet, reduce weight, and increase physical activity.

Same as for placebo, but with metformin titrated up to 875 mg twice a day.

16-session curriculum covering diet, exercise, and behavior modification taught by case managers on a 1:1 basis in the first 24 wks. Flexible, culturally sensitive, and individualized. Subsequent individual (typically monthly) and group sessions with case managers to reinforce behavioral change.

Clinical assessment, with baseline health education pamphlet on reducing cardiovascular risk factors and advice to quit smoking.

Cognitive-behavioral program aimed at preventing rises in LDL cholesterol and weight gain and increasing leisure-time activity. Intensive group program in the first 6 mos, then follow-up individual and group sessions from mos 6–54. Weight loss goal was 5–15 lbs, depending on baseline weight. Participants were asked to lower dietary fat intake and daily caloric intake. Lifestyle approach to increasing physical activity to expenditure of 1,000–1,500 kcal/wk.

General oral and written information about diet and exercise at baseline and at subsequent annual visits. 3-day food diary at baseline and at each annual visit.

Detailed advice about how to achieve weight loss, diet, and exercise goals. Participants met with nutritionist 7 times over first yr, then every 3 mos. Dietary advice was tailored to each participant based on quarterly food diaries and included behavioral modification tips. Participants received individual guidance on increasing physical activity level. Endurance exercise (walking, jogging, swimming, aerobic ball games, or skiing) was recommended as a way of increasing aerobic capacity. Supervised progressive, individualized circuit-type resistance training also offered for improving functional capacity and strength.

*continue*

**Appendix Table 3. Intensive Counseling Intervention Descriptions† (cont)**

<b>Study, Year</b>	<b>Intervention</b>	<b>Intervention Setting</b>	<b>Intervention Delivery</b>
Fogelholm et al, 2000 <sup>76</sup>	Control (40-wk follow-up after 12-wk weight reduction program)	Not noted	Nutritionist (weight loss phase)
	Walking program (4.2 MJ/wk target expenditure) following 12-wk weight reduction program	Not noted	Nutritionist (weight loss phase), exercise instructor (maintenance phase)
	Walking program (8.4 MJ/wk target expenditure) following 12-wk weight reduction program	Not noted	Nutritionist (weight loss phase), exercise instructor (maintenance phase)
Jakicic et al, 1999 <sup>72</sup>	Short-bout exercise	Not noted	Nutritionists, exercise physiologists, and behavioral therapists
	Long-bout exercise	Not noted	Nutritionists, exercise physiologists, and behavioral therapists
	Short-bout exercise with equipment	Not noted	Nutritionists, exercise physiologists, and behavioral therapists
Jones et al, 1999 <sup>69</sup>	Control	Not noted	Study nurse
	Weight loss	Not noted	Registered dietitian
Sbrocco et al, 1999 <sup>74</sup>	Behavioral choice treatment	Not noted	Clinical psychologist or clinical social worker (also a psychology graduate student) with extensive experience in the behavior treatment of obesity. Two inexperienced graduate students (psychology) were co-leaders.
	Traditional behavioral treatment	Not noted	Clinical psychologist or clinical social worker (also a psychology graduate student) with extensive experience in the behavior treatment of obesity. Two inexperienced graduate students (psychology) were co-leaders.

**Appendix Table 3. Intensive Counseling Intervention Descriptions† (cont)**

**Counseling and Behavioral Description**

12-wk weight reduction program (wk 1: low energy diet based on meal exchange; wks 2–9 VLCD; wks 10–12: low energy diets), with weekly small groups (5–12 participants) receiving instruction on diet, weight maintenance, relapse prevention. No increase in habitual exercise in the 40-wk follow-up.

12-wk weight reduction program as above. In maintenance program, each participant was prescribed a weekly walking time and walked with a heart rate monitor. One weekly walking session was supervised. All persons participated in weekly meetings in small groups throughout the maintenance program, conducted by an exercise instructor. Educational material was distributed monthly. Weekly homework included monitoring of high-risk situations for overeating. Problems in diet and prevention of relapse were discussed in the meetings.

12-wk weight reduction program, then 40-wk walking weight maintenance program as described in the 4.2 MJ program above; only difference was increased targeted energy expenditure.

Behavioral weight loss program: group treatment meetings of diminishing frequency (weekly in mos 1–6, biweekly in mos 7–12, monthly in wks 13–18). Meetings focused on behavioral strategies for modifying eating and exercise behaviors. Participants were instructed to reduce daily energy and fat intake. Caloric goal based on baseline weight, with goal of 0.45–0.9 kg loss per wk. Fat intake goal was 20% of total intake. Food diaries reviewed weekly, with feedback from interventionists.  
Exercise: same volume of exercise, all home based, in all 3 groups. Participants instructed to exercise 5 days/wk: initially 20 mins/day (wks 1–4), increasing to 40 mins/day by wk 9. Exercise was divided into multiple 10-min bouts performed at convenient times in the day.

Behavioral weight loss program: as in the short-bout exercise arm.  
Exercise: daily total exercise amounts as described in the short-bout exercise arm. Exercise was to be performed in 1 long bout.

Behavioral weight loss program as in the short-bout exercise arm.  
Exercise: daily total exercise amounts as described in the short-bout exercise arm. Participants were provided with motorized home treadmills.

Participants were told that they should lose weight, but received no formal diet counseling or group support.

Patients individually counseled within 10 days of randomization and 2–4 wks later. Content focused on food selection and preparation, and weight reduction goals were established. No exercise advice. They met in groups twice monthly for 3 mos, then every 3–6 mos.

13 weekly 1.5-hr group sessions with 5–7 members per group. Participants received 2-wk meal plans and recipe booklets for a low fat (25%) diet: 1,800 kcal/day. Diaries reviewed, with immediate feedback each session—including graphs of daily fat and caloric intake and a list of highest-fat foods and some alternatives. Participants encouraged to eat at a constant calorie level. Self-monitoring phased out before acute treatment ended. Participants were encouraged to complete a walking program 30 mins/day, 3 days/wk in a single bout. No formal exercise groups, but daily exercise logs.  
Stated purpose: to stop dieting and to view eating as a choice; to expect slower weight loss than they had experienced in the past, but more permanent change. Health behavior including food choice, avoiding exercise, eating behaviors discussed as choices designed to achieve certain outcomes. Individuals taught to identify their choices and the outcomes controlling these choices and to focus on learning to eat in a manner consistent with a reasonable eventual end-goal weight, rather than focusing on how quickly weight can be lost.

Weekly group sessions, meal plans, recipes, food diaries, and exercise as above, but with 1,200 kcal/day diet. Stated purpose: to promote substantial weight loss and to help develop habits and strategies to maintain this loss. Standard behavioral weight management techniques (eg, self-monitoring, stimulus control, and behavioral substitution) were taught. Participants were encouraged to avoid eating and purchasing high-calorie foods and to lose weight so they could then maintain these changes; they were taught to understand their reasons for eating and to engage in problem-solving to determine other methods to respond to stress.

*continue*

**Appendix Table 3. Intensive Counseling Intervention Descriptions† (cont)**

<b>Study, Year</b>	<b>Intervention</b>	<b>Intervention Setting</b>	<b>Intervention Delivery</b>
Ashley et al, 2001 <sup>82</sup>	Dietitian-led lifestyle intervention	Not noted	Registered dietitian
	Dietitian-led lifestyle intervention with meal replacements	Not noted	Registered dietitian
	Primary care office intervention with meal replacements	Physician office	Primary care physician (2/3 of visits) or registered nurse (1/3 of visits)
Wadden et al, 2001 <sup>68</sup>	Sibutramine alone	Not noted	Physician
	Sibutramine + lifestyle	Not noted	Physician (outcomes monitoring) doctoral-level psychologists (counseling)
	Sibutramine + lifestyle + diet	Not noted	Physician (outcomes monitoring) doctoral-level psychologists (counseling)
Wing and Anglin, 1996 <sup>78</sup>	Behavior therapy with LCD	Not noted	Multidisciplinary team (all white)
	Behavior therapy with intermittent VLCD	Not noted	Multidisciplinary team (all white)



**Appendix Table 3. Intensive Counseling Intervention Descriptions† (cont)**

**Counseling and Behavioral Description**

26 1-hr sessions over 1 yr. Participants received instruction manuals that included lessons based on an established weight control program (LEARN). Diet included a LCD (1,200 kcal/day, with ≤ 30% of calories from fat), using standard recommendations for food groups and portion sizes. Activity instruction included walking up to 10,000 steps/day, measured by a supplied pedometer. Self-monitoring of food intake and energy expenditure in diaries. Specific to this group, participants attended small (8–10 people) classes led by a registered dietitian. Classes were weekly for 3 mos, then biweekly for 3 mos, then monthly for 4 mos. Diet was made up of conventional food items.

As in the traditional group above, instruction manuals for dieting, 1,200-kcal diet, and exercise instructions with pedometer use and self-monitoring. Sessions with registered dietitian as above. However, 2 of the 3 main meals were replaced with meal-replacement shakes or bars (reduced to 1 main meal if goal reached and maintained).

26 biweekly 10–15 min individual sessions over 1 yr, with a focus of helping patients lose weight (although other related medical problems were also discussed). Diet prescription with meal replacements as in the “dietitian-led with meal replacement” plan above. During each visit, diet, behavior modification, and physical activity habits were reviewed, and questions answered about the diet instructions.

Baseline meeting with a physician who described medication use and the importance of lifestyle modification. A balanced diet (1,200–1,500 kcal/day) was prescribed. Gradually increased exercise (typically walking) to 4–5 sessions/wk, each of 30–40 mins duration. Literature supporting these instructions was disseminated. Over the trial, patients had 10 brief (5–10 min) follow-up visits with the physician (wks 2, 4, 8, 12, 16, 20, 24, 32, 40, 52). No lifestyle counseling or instruction for self-monitoring of lifestyle change.

Physician visits on same schedule as sibutramine alone group. Additionally, in the first 20 wks, they attended weekly psychologist-led group lifestyle modification sessions. They were prescribed the same diet and exercise goals as the drug-only group but were given behavioral strategies for achieving them and were asked to self-monitor food intake and physical activity for at least 16 wks. Behavioral topics discussed at weekly sessions included stimulus control, slowed rate of eating, social support, and cognitive restructuring. During wks 24–52, sessions focused on skills for maintenance of weight loss.

Identical intervention to the sibutramine plus lifestyle group, with the addition of the first 16 wks prescription of a 1,000 kcal/day portion-controlled diet (4 servings/day of a liquid nutritional supplement with an evening balanced meal). After wk 16, gradually decreased consumption of liquid supplement, with 1,200–1,500 kcal/day diet of conventional food diet by wk 20 (similar to the patients in the other 2 arms).

1 yr of weekly sessions, including review of self-monitoring records, weighing, and a lecture/discussion on nutrition, behavioral techniques, or exercise. Topics included stimulus control, goal setting, and self-monitoring of diet and exercise. Participants encouraged to gradually increase activity until walking 2 miles/day, 5 days/wk. Participants followed a LCD (1,000–1,200 kcal/day), with < 30% calories from fat.

Counseling and behavioral therapy as above for diet and exercise. Intermittent VLCD in wks 1–12 and 24–36. During VLCD intervals, goal consumption of approximately 500 kcal/day, either as liquid formula or lean meat, fish, or fowl. After each VLCD, other foods gradually reintroduced until consumption of 1,000–1,200 kcal/day was reached.